



---

Year: 2023

---

## VGLL2-NCOA2 leverages developmental programs for pediatric sarcomagenesis

Watson, Sarah ; LaVigne, Collette A ; Xu, Lin ; Surdez, Didier ; Cyrta, Joanna ; Calderon, Delia ; Cannon, Matthew V ; Kent, Matthew R ; Silvius, Katherine M ; Kucinski, Jack P ; Harrison, Emma N ; Murchison, Whitney ; Rakheja, Dinesh ; Tirode, Franck ; Delattre, Olivier ; Amatruda, James F ; Kendall, Genevieve C

**Abstract:** Clinical sequencing efforts are rapidly identifying sarcoma gene fusions that lack functional validation. An example is the fusion of transcriptional coactivators, VGLL2-NCOA2, found in infantile rhabdomyosarcoma. To delineate VGLL2-NCOA2 tumorigenic mechanisms and identify therapeutic vulnerabilities, we implement a cross-species comparative oncology approach with zebrafish, mouse allograft, and patient samples. We find that VGLL2-NCOA2 is sufficient to generate mesenchymal tumors that display features of immature skeletal muscle and recapitulate the human disease. A subset of VGLL2-NCOA2 zebrafish tumors transcriptionally cluster with embryonic somitogenesis and identify VGLL2-NCOA2 developmental programs, including a RAS family GTPase, ARF6. In VGLL2-NCOA2 zebrafish, mouse, and patient tumors, ARF6 is highly expressed. ARF6 knockout suppresses VGLL2-NCOA2 oncogenic activity in cell culture, and, more broadly, ARF6 is overexpressed in adult and pediatric sarcomas. Our data indicate that VGLL2-NCOA2 is an oncogene that leverages developmental programs for tumorigenesis and that reactivation or persistence of ARF6 could represent a therapeutic opportunity.

DOI: <https://doi.org/10.1016/j.celrep.2023.112013>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-254364>

Journal Article

Published Version



The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.


Originally published at:

Watson, Sarah; LaVigne, Collette A; Xu, Lin; Surdez, Didier; Cyrta, Joanna; Calderon, Delia; Cannon, Matthew V; Kent, Matthew R; Silvius, Katherine M; Kucinski, Jack P; Harrison, Emma N; Murchison, Whitney; Rakheja, Dinesh; Tirode, Franck; Delattre, Olivier; Amatruda, James F; Kendall, Genevieve C (2023). VGLL2-NCOA2 leverages developmental programs for pediatric sarcomagenesis. *Cell Reports*, 42(1):112013.

DOI: <https://doi.org/10.1016/j.celrep.2023.112013>

# VGLL2-NCOA2 leverages developmental programs for pediatric sarcomagenesis

## Graphical abstract



## Authors

Sarah Watson, Collette A. LaVigne,  
Lin Xu, ..., Olivier Delattre,  
James F. Amatruda, Genevieve C. Kendall

## Correspondence

jamatruda@chla.usc.edu (J.F.A.),  
genevieve.kendall@nationwidechildrens.  
org (G.C.K.)

## In brief

Watson et al. use a cross-species comparative approach to develop zebrafish and mouse models of a rare fusion-driven pediatric sarcoma. These models recapitulate the human disease, and the integration of these systems identifies a conserved developmental target, ARF6. ARF6 cooperates with the primary oncogenic driver, representing a potential therapeutic opportunity.

## Highlights

- VGLL2-NCOA2 is transforming in transgenic zebrafish and mouse allograft models
- Tumors resemble immature skeletal muscle and express developmental genes
- Zebrafish, mouse, and human tumors overexpress a small GTPase, ARF6
- ARF6 and VGLL2-NCOA2 genetically cooperate for pro-tumorigenic activity



## Article

# VGLL2-NCOA2 leverages developmental programs for pediatric sarcomagenesis

Sarah Watson,<sup>1,2,17</sup> Collette A. LaVigne,<sup>3,17</sup> Lin Xu,<sup>4</sup> Didier Surdez,<sup>1,5</sup> Joanna Cyrta,<sup>6</sup> Delia Calderon,<sup>7,8</sup> Matthew V. Cannon,<sup>7</sup> Matthew R. Kent,<sup>7</sup> Katherine M. Silvius,<sup>7</sup> Jack P. Kucinski,<sup>7,8</sup> Emma N. Harrison,<sup>7</sup> Whitney Murchison,<sup>9</sup> Dinesh Rakheja,<sup>9,10</sup> Franck Tirode,<sup>11</sup> Olivier Delattre,<sup>1,12,13</sup> James F. Amatruda,<sup>14,15,18,\*</sup> and Genevieve C. Kendall<sup>7,16,18,19,\*</sup>

<sup>1</sup>Institut Curie Research Center, Paris Sciences et Lettres (PSL) Research University, INSERM U830, 75005 Paris, France

<sup>2</sup>Institut Curie, Paris Sciences et Lettres (PSL) Research University, Medical Oncology Department, 75005 Paris, France

<sup>3</sup>Department of Molecular Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA

<sup>4</sup>Quantitative Biomedical Research Center, Department of Population and Data Sciences, UT Southwestern Medical Center, Dallas, TX 75390, USA

<sup>5</sup>Balgrist University Hospital, Faculty of Medicine, University of Zürich (UZH), 8008 Zürich, Switzerland

<sup>6</sup>Institut Curie, Paris Sciences et Lettres (PSL) Research University, Department of Pathology, 75005 Paris, France

<sup>7</sup>Center for Childhood Cancer, The Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH 43205, USA

<sup>8</sup>Molecular, Cellular, and Developmental Biology Ph.D. Program, The Ohio State University, Columbus, OH 43210, USA

<sup>9</sup>Department of Pediatrics, UT Southwestern Medical Center, Dallas, TX 75390, USA

<sup>10</sup>Department of Pathology, UT Southwestern Medical Center, Dallas, TX 75390, USA

<sup>11</sup>University Lyon, Université Claude Bernard Lyon 1, Cancer Research Center of Lyon, INSERM 1052, CNRS 5286, Centre LéonBérard, 69008 Lyon, France

<sup>12</sup>Institut Curie, SIREDO Pediatric Center, 75005 Paris, France

<sup>13</sup>Institut Curie Hospital Group, Unité de Génétique Somatique, 75005 Paris, France

<sup>14</sup>Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA 90027, USA

<sup>15</sup>Departments of Pediatrics and Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA

<sup>16</sup>Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH 43205, USA

<sup>17</sup>These authors contributed equally

<sup>18</sup>These authors contributed equally

<sup>19</sup>Lead contact

\*Correspondence: [jamatruda@chla.usc.edu](mailto:jamatruda@chla.usc.edu) (J.F.A.), [genevieve.kendall@nationwidechildrens.org](mailto:genevieve.kendall@nationwidechildrens.org) (G.C.K.)

<https://doi.org/10.1016/j.celrep.2023.112013>

## SUMMARY

Clinical sequencing efforts are rapidly identifying sarcoma gene fusions that lack functional validation. An example is the fusion of transcriptional coactivators, VGLL2-NCOA2, found in infantile rhabdomyosarcoma. To delineate VGLL2-NCOA2 tumorigenic mechanisms and identify therapeutic vulnerabilities, we implement a cross-species comparative oncology approach with zebrafish, mouse allograft, and patient samples. We find that VGLL2-NCOA2 is sufficient to generate mesenchymal tumors that display features of immature skeletal muscle and recapitulate the human disease. A subset of VGLL2-NCOA2 zebrafish tumors transcriptionally cluster with embryonic somitogenesis and identify VGLL2-NCOA2 developmental programs, including a RAS family GTPase, ARF6. In VGLL2-NCOA2 zebrafish, mouse, and patient tumors, ARF6 is highly expressed. ARF6 knockout suppresses VGLL2-NCOA2 oncogenic activity in cell culture, and, more broadly, ARF6 is overexpressed in adult and pediatric sarcomas. Our data indicate that VGLL2-NCOA2 is an oncogene that leverages developmental programs for tumorigenesis and that reactivation or persistence of ARF6 could represent a therapeutic opportunity.


## INTRODUCTION

With the broader implementation of clinical sequencing efforts, there has been a significant increase in the number of gene fusions that have been identified in patient tumors. Particularly in sarcomas, there is a predilection for fusion oncogenes with a predicted 20%–49% of sarcomas containing a gene fusion event.<sup>1–4</sup> In pediatric sarcomas, there are typically few other

somatic mutations, highlighting fusions as the defining oncogenic drivers in these diseases.<sup>5–7</sup> However, developing cell culture or animal models of these newly identified fusions is challenging, hindering the verification of their role in tumorigenesis and the identification of potential targeted therapeutics. A pressing need exists for tractable genetic models to understand the shared and divergent biology between genetic drivers, and ultimately provide a platform to identify mechanism based therapies.







(legend on next page)



One example of a recently discovered fusion gene is *VGLL2-NCOA2*, which was identified from a cohort of congenital pediatric sarcomas that did not contain the classical pediatric sarcoma gene fusions.<sup>4,8</sup> Both vestigial-like family member 2 (*VGLL2*) and nuclear receptor coactivator 2 (*NCOA2*) are transcriptional coactivators, but their function in this gene fusion has not been studied. *VGLL2* (previously named *VITO-1*) plays a role in muscle development and targets TEA domain transcription factor (TEAD) proteins to their appropriate contexts during the differentiation process.<sup>9–11</sup> Additionally, in zebrafish models, *vgll2a* is required for neural crest cell survival and craniofacial development.<sup>12</sup> *NCOA2* is a common 3' fusion partner in non-spindle cell sarcoma contexts; examples include *HEY1-NCOA2* in mesenchymal chondrosarcoma, *MEIS1-NCOA2* in genitourinary and gynecologic tract spindle cell sarcomas and intraosseous rhabdomyosarcomas, and *PAX3-NCOA2* in alveolar rhabdomyosarcoma.<sup>13–17</sup> Suggestively, *TEAD1-NCOA2* fusions have also been identified in infantile rhabdomyosarcoma, indicating converging developmental processes for this subtype.<sup>18,19</sup>

The *VGLL2-NCOA2* fusion has been described in multiple patients by multiple groups. There are two forms of the gene fusion, *VGLL2* exons 1–2 and either *NCOA2* exons 13–23 or 14–23. The translocation involves two genomic events, an inversion of *VGLL2*, followed by a break and chromosomal translocation of chromosomes 6 and 8. These fusions are the defining genetic features of the disease; however, pathologically and transcriptionally, the tumors are heterogeneous.<sup>4,8,20</sup> The biological explanation for this heterogeneity remains unclear.

Clinically, *VGLL2-NCOA2* tumors typically present between 0 and 1 year of age and have a spindle and sclerosing cellular morphology.<sup>4,8,18,20–22</sup> Fusion-driven congenital rhabdomyosarcomas generally have a favorable prognosis with successful surgery and chemotherapy.<sup>8</sup> However, non-resectable tumors are challenging to treat, and chemotherapy exposure carries a significant risk of short- and long-term adverse effects. Moreover, clinical outcomes of *VGLL2-NCOA2* rearranged tumors are variable. Recently, a case study with four *VGLL2* rearranged tumors described three patients that had multi-metastatic spread, and two that died from disease. This study suggests that complete surgical resection is critical (but not always attainable) for long-term benefit, and that *VGLL2* fusions are capable of aggressive disease.<sup>22</sup> Given that these tumors occur at a developmentally sensitive age, effective targeted therapies are critically needed to improve disease outcomes and ameliorate

off-target effects from toxic and generalized therapies. Therefore, we set out to test the tumorigenic capacity of this fusion gene, define its oncogenic program, and identify potential therapeutic targets.

Previously, we described a mosaic strategy using vertebrate transgenic zebrafish models that addresses the need to readily generate animal models that recapitulate the genetics and presentation of the human disease. This strategy has been successful for *PAX3-FOXO1*-driven rhabdomyosarcoma and *CIC-DUX4*-mediated Ewing-like sarcoma, indicating that zebrafish are a powerful tool for personalized medicine approaches and for the study of rare cancers and disease.<sup>23,24</sup> Here, we implement a functional genomics approach to generate human *VGLL2-NCOA2* fusion-oncogene-driven zebrafish and mouse allograft models of tumorigenesis. We find that the fusion is indeed sufficient for aggressive tumorigenesis in the zebrafish and mouse systems, resulting in tumors that recapitulate histological and molecular features of the human disease. Zebrafish *VGLL2-NCOA2* tumors express markers indicative of arrested skeletal muscle development and poor differentiation. RNA sequencing (RNA-seq) of zebrafish and mouse allograft tumors identified *ARF6*, a small GTPase, as an overexpressed and potentially druggable target. *ARF6* is expressed not only in human *VGLL2-NCOA2* tumors but also across a panel of pediatric sarcomas and other cancers, whereas there is no expression in normal tissue counterparts. We demonstrate in cell culture systems that *ARF6* and *VGLL2-NCOA2* genetically cooperate to inhibit myogenesis, and that *ARF6* knockout suppresses *VGLL2-NCOA2*-mediated colony formation. Our study suggests that this congenital rhabdomyosarcoma fusion oncogene coopts developmental programs to induce its effects, and that zebrafish are high-fidelity models of these systems. Further, these models have the potential to identify tumor-specific therapeutic opportunities for these rare diseases.


## RESULTS

### ***VGLL2-NCOA2* is an oncogene and is tumorigenic in zebrafish**

Previously, we and others have shown that *VGLL2-NCOA2* is a fusion gene exclusively found in a subset of congenital rhabdomyosarcomas.<sup>4,8</sup> Five patients under the age of five presented with soft tissue tumors that were originally diagnosed as embryonal rhabdomyosarcomas. Clinical sequencing of patient tumors

#### **Figure 1. A zebrafish model of human *VGLL2-NCOA2*-driven tumorigenesis**

- (A) Zebrafish were injected at the one-cell stage with plasmid DNA carrying the human fusion gene *VGLL2-NCOA2* driven by the CMV promoter and tagged with GFP2A, and Tol2 transposase mRNA to stably integrate the construct. The GFP+ embryos were tracked from 1 to 12 months for tumor formation.
- (B) Tumor incidence curve of one independent experiment showing  $n = 108$  adult fish injected with CMV-GFP2A-*VGLL2NCOA2* compared with  $n = 42$  adult sibling fish injected with CMV-GFP2A-pA and log rank (Mantel-Cox) test performed with  $p < 0.0001$ . All fish that survived past 30 days of age are included. This experiment was repeated in three independent cohorts, with similar tumor incidence curves (data not shown).
- (C) Distribution of CMV-*VGLL2NCOA2* tumors classified by location as depicted on the inset fish schematic.
- (D) Tumor onset curve for fish with a CMV-*VGLL2NCOA2*-driven tumor, stratified by location on the fish as defined in (C). Log rank (Mantel-Cox) analysis showed significant difference between the tumor onset of ventral tumors and all other tumors ( $p = 0.0479$ ).
- (E) Representative CMV-*VGLL2NCOA2*-injected fish with tumors classified by location. For each fish, brightfield and GFP fluorescent images are overlaid and shown above the H&E stain of a transverse section through the GFP+ area. The top left text is the unique fish identification number, and the top right is the age of the fish when the tumor was resected. Scale bars for GFP and brightfield overlay, 2 mm. Scale bars for H&E and H&E inset, 500 and 100  $\mu\text{m}$ , respectively.
- (F) High-magnification images (100 $\times$  objective) of H&E stain of transverse sections through representative tumors from the tail, back, and ventral regions. Scale bars, 50  $\mu\text{m}$ .



(legend on next page)



identified the presence of a VGLL2-NCOA2 fusion. Table S1 describes the clinical presentation of each case that was identified in Watson et al.<sup>4</sup> The fusion in all tumors contains an intronic breakpoint in VGLL2 that results in the incorporation of the first two exons of VGLL2. However, there were two intronic breakpoints seen in NCOA2; five tumors had a breakpoint that resulted in inclusion of exons 14 through 23 of NCOA2, whereas one tumor had an additional fusion product with the inclusion of exons 13–23 (Table S1; Figure S1).<sup>4</sup>

The coding sequence of the human fusion was cloned out of a primary patient tumor that harbored the NCOA2 exon 14 breakpoint (Figure S1A). Gateway cloning was used to generate a cytomegalovirus (CMV)-GFP2A-VGLL2NCOA2 construct for expression of the human fusion gene in zebrafish systems. The cassette is flanked on both sides by Tol2 sites, which facilitates genomic integration when injected with Tol2 mRNA (Figure 1A).<sup>25</sup> The viral 2A sequence allows for GFP and VGLL2-NCOA2 to be transcribed on the same mRNA but to function as independent proteins. We injected this expression construct and Tol2 mRNA into one-cell-stage wild-type zebrafish embryos and observed robust GFP expression at 24 h post fertilization (hpf) in >95% of embryos (data not shown). Zebrafish were monitored for tumor development by observing gross morphology and GFP expression, which served as a proxy for fusion-oncogene expression. Zebrafish presented with tumors as early as 1 month, with 20% of zebrafish developing tumors by 50 days, and ~30% by 6 months. In control cohorts injected with CMV-GFP-pA, tumors were never observed (Figure 1B). The sufficiency of the VGLL2-NCOA2 fusion to generate tumors in zebrafish confirms its function as an oncogene.

We classified all generated tumors by location on the fish, binning the fish as depicted in Figure 1C. We observed that tumors arising on the tail were the most common (44%; n = 33 out of 75), back and head tumors occurred in equal numbers (23%; n = 17 out of 75 and 20%; n = 15 out of 75 respectively), and ventral tumors were the least common (9%; n = 7 out of 75) (Figure 1C). The tumor onset was similar for each location with the exception of the ventral tumors, which arose later compared with the other tumor locations (log rank,  $p < 0.05$ ) (Figure 1D). Interestingly, three zebrafish presented with more than one tumor around 47 days of age (Figures 1C, 3C, Table S2).

Shown in Figure 1E is the gross morphology and GFP fluorescence of four representative zebrafish tumors and their corresponding hematoxylin and eosin (H&E) stains of transverse sections through the GFP-positive (GFP+) region. All four of

these tumors are mesenchymal tumors diagnosed as sarcomas, with infiltrating cells, and a variety of cell types including spindle cells, round cells, and pleomorphic cells, although in differing proportions. All tumors are mitotically active. The tumors contain dispersed nuclear chromatin and poorly defined cell membranes; prominent nucleoli are seen in the head tumor. Fascicular arrangements of cells are observed in the tail and back tumors, and there is a notable lack of background stroma. In the ventral tumor, there is a higher proportion of stroma and more pleomorphic and spindle cells. Collagen is present in variable amounts in the ventral tumor. In the head tumor, the predominant cell types are pleomorphic and round cells with accompanying necrosis. Altogether, these tumors are consistent with the histology of human sarcomas. Further examples of this histology are presented as higher-magnification images in Figure 1F.

We also generated constructs in which GFP-tagged VGLL2-NCOA2 was driven by the following zebrafish promoters: MCS-beta-globin-Splice Acceptor,  $\beta$ -actin, ubiquitin, and unc503. Following zebrafish microinjection, we observed GFP expression at 24 h post fertilization, indicating successful genomic integration of the constructs (Figure S2A). With MCS-beta-globin-SA-GFP2A-VGLL2NCOA2, we observed a total of three fish out of 42 that presented with tumors, two diagnosed as sarcomas, and one as neuroblastoma/retinoblastoma (Figure S2B). The other promoters failed to produce any tumors, although some GFP+ adult fish were observed (Figure S2C). Given the low incidence, we focused our efforts on the CMV-driven model, which recapitulated the human disease with the highest fidelity. All zebrafish tumors in the remainder of the study are generated from the CMV-GFP2A-VGLL2NCOA2 construct.

### VGLL2-NCOA2 zebrafish tumors recapitulate the human disease

To validate that zebrafish tumors expressed the VGLL2-NCOA2 fusion at the protein level, we performed immunohistochemistry on serial transverse sections of zebrafish tumors using a human NCOA2 antibody (Figure 2A). The tumor cells identified with H&E staining were also positive for VGLL2-NCOA2. Additionally, a wild-type zebrafish control section was largely negative for NCOA2, indicating that VGLL2-NCOA2 is specifically expressed in the GFP+ tumors. We confirmed by RNAscope that VGLL2-NCOA2 tumors expressed the zebrafish orthologs of diagnostic rhabdomyosarcoma markers, including *myod1*, *myog*, and *desma*. Shown are examples of their expression patterns in

### Figure 2. Zebrafish VGLL2-NCOA2 tumors recapitulate the human disease


(A) Transverse sections through the GFP+ tumors were stained with H&E, and the subsequent step section stained with a human anti-NCOA2 antibody to detect the VGLL2-NCOA2 fusion. All n = 9 zebrafish tumors stained were positive. A transverse section was taken through a control wild-type zebrafish, and shown are the H&E and subsequent anti-NCOA2 antibody stain. Scale bars, 500  $\mu$ m.

(B) Representative RNAscope of transverse sections from wild-type zebrafish (portraying normal skeletal muscle expression) or zebrafish with VGLL2-NCOA2 tumors showing expression of *myod1*, *myog*, or *desma* (green), *Pcna* (purple), or DNA (blue). Scale bars, 50  $\mu$ m. Five wild-type or tumor samples were assessed in total, with results presented in Table S3.

(C) RNA-seq data of zebrafish VGLL2-NCOA2 tumors (n = 18) and mature skeletal muscle (n = 7) were compared with their human counterpart (VGLL2-NCOA2 tumors n = 5 from Watson et al.<sup>4</sup> and mature skeletal muscle n = 803 from GTEx version 8) in an AGDEX analysis. Plotted in blue and red are genes that are shared as differentially expressed between the zebrafish and human VGLL2-NCOA2 tumors. The statistics of the AGDEX analysis are shown in the bottom right, as well as the p value generated by permutation analysis of randomly sampled data.

(D) Gene set enrichment analysis associated with the n = 6,348 genes upregulated or n = 4,313 downregulated in (C). Plotted is the normalized enrichment score for each sub-ontology.






**Figure 3. Gene expression profiles of VGLL2-NCOA2 zebrafish tumors cluster with developmental time points**

(A) Principal-component analysis (PCA) of RNA-seq data of zebrafish development time points from White et al.<sup>26</sup> and VGLL2-NCOA2 zebrafish tumors from this study. All FASTQ files were processed by the same computational pipeline to minimize computational batch effects. Colors indicate location of the tumor on the fish: back tumors in orange, ventral tumors in blue, head tumors in green, and tail tumors in purple. In the PCA, principal component 1 (PC1) describes the most variance but is presented to appreciate differences in PC2, which best discriminates tumor cohorts.

(B) Embryonic stages labeled as per the Zebrafish Information Network (ZFIN).

(C) Brightfield and GFP overlaid images of a subset of the VGLL2-NCOA2 tumors used in (A). Scale bars, 2 mm.



**Figure 4. VGLL2-NCOA2 reactivates developmental genes in zebrafish, mouse allograft, and human tumors**

RNA-seq was performed on n = 18 zebrafish VGLL2-NCOA2 tumors, n = 7 adult zebrafish mature skeletal muscle samples, and n = 3 pooled samples of larval zebrafish from segmentation time points at 1–4 somites, 14–19 somites, and 20–25 somites (10.33, 16, and 19 h post fertilization at 28°C, respectively).

(A) Venn diagram depicting the genes differentially regulated in the developmental time points and tumors compared with mature skeletal muscle, with n = 27 genes differentially regulated in both tumors and development. A false discovery rate (FDR) of 0.01 was used for genes to be included in this analysis.

(B) Plot of FPKM values from n = 8 genes downregulated in developmental time points and tumors compared with mature skeletal muscle. The error bars represent the mean ± SD.

(C) Plot of FPKM values from n = 19 genes upregulated in developmental time points and tumors compared with mature skeletal muscle. The error bars represent the mean ± SD.

(D) Comparison of the expression of these 27 developmental genes in a mouse VGLL2-NCOA2-driven allograft model. Plotted is the fold change of these 27 genes in VGLL2-NCOA2 zebrafish tumors (n = 18) compared with mature skeletal muscle (n = 7), and in C2C12-VGLL2NCOA2 mouse allografts (n = 8) compared

(legend continued on next page)

wild-type skeletal muscle compared with tumors (Figure 2B). These muscle markers are used to clinically characterize the human disease (Table S2).<sup>4,8</sup> Further, tumor samples had high levels of PcnA expression (Figure 2B). These findings were consistent across multiple tumors, with synthesized data presented in Table S3. The RNAscope findings are consistent with our RT-PCR data showing that VGLL2-NCOA2 tumors expressed the fusion at the mRNA level, and, except for one tumor, expressed the muscle markers *myoD1*, *myog*, and *desma* (Figure S3A).

We then performed RNA-seq on a cohort of zebrafish VGLL2-NCOA2 sarcomas to determine how well they transcriptionally recapitulate the human disease. To do this, we used a comparison of zebrafish or human VGLL2-NCOA2 tumors to mature skeletal muscle. VGLL2-NCOA2 zebrafish and human tumor expression signatures relative to mature skeletal muscle were then compared in an agreement of differential expression (AGDEX) analysis with a minimum of 5,000 permutations (Figure 2C).<sup>4,24,27</sup> There were 10,661 genes that were shared and differentially expressed between the zebrafish and human VGLL2-NCOA2 tumor types compared with mature skeletal muscle. In Figure 2C, the cosine of the angle (cos) and difference of proportions (dop) statistics are both positive, suggesting the zebrafish model recapitulates the human disease. This is supported by a permutation analysis by randomly sampling from kernel density distributions matching the distributions of the original data indicating an enrichment of differentially expressed genes shared between human and zebrafish tumors (Figure 2C). Gene set enrichment analysis of these 10,661 overlapping and differentially expressed genes revealed multiple biological pathway terms related to activation of extracellular structure organization and inhibition of skeletal muscle differentiation processes (Figures 2D and S3). This significant overlap between zebrafish and human VGLL2-NCOA2 sarcomas is also observed when compared with CIC-DUX4 Ewing-like sarcoma rather than skeletal muscle (Figures S3B and S3C). Importantly, in contrast, there was little overlap between a KRAS-driven rhabdomyosarcoma zebrafish tumor model and VGLL2-NCOA2 human or zebrafish tumors (Figures S3D and S3E), highlighting the power of this strategy. Overall, these data support implementing zebrafish tumor models to understand human VGLL2-NCOA2 disease biology.

### VGLL2-NCOA2 leverages developmental genes and programs during tumor formation

Given the early onset of the tumors in the human and zebrafish cohorts, and the possible link to development observed in the RNA-seq data, we hypothesized that the fusion oncogene was co-opting developmental genes to promote tumorigenesis. RNA-seq data from 18 zebrafish developmental time points from one-cell to 5 days post fertilization were analyzed along-

side VGLL2-NCOA2 zebrafish tumors and were plotted using the first three principal components.<sup>26</sup> This analysis revealed a large cohort of tumors clustered with the developmental time points of segmentation (Figure 3A; stage S9–S11). This specific developmental time point is striking as it corresponds to somitic muscle development in zebrafish (Figure 3B). The tumors that clustered with segmentation include the tumors on the head (green, Figures 3A and 3C), tail (purple, Figures 3A and 3C), and several of the ventral tumors (blue, Figures 3A and 3C). However, the tumors on the back (orange, Figures 3A and 3C) did not cluster with this group, instead forming a second cluster distant from the developmental trajectory.


To identify genes in VGLL2-NCOA2 tumors that direct this clustering with segmentation, we performed a differential gene expression analysis from the RNA-seq data. First, the cohort of  $n = 18$  VGLL2-NCOA2 zebrafish tumors was compared with  $n = 7$  mature zebrafish skeletal muscle samples, identifying 385 differentially regulated genes. Next,  $n = 3$  samples of embryonic zebrafish during somitogenesis (1–4 somites, 14–19 somites, and 20–25 somites) were compared with mature zebrafish skeletal muscle; and 303 differentially regulated genes were found. Then, these 385 and 303 gene sets were intersected to identify 27 genes shared in both development and tumor datasets as differentially expressed compared with mature skeletal muscle (Figure 4A). These 27 genes represent potential VGLL2-NCOA2 signatures that are reactivated, inappropriately persist, or are never turned on in tumors. To demonstrate the magnitude of this expression, the fragments per kilobase of exon per million mapped fragments (FPKM) of these 27 genes was plotted, including genes downregulated in the tumors and developing muscle compared with mature skeletal muscle (Figure 4B), and genes that were conversely upregulated in tumors and development compared with mature skeletal muscle (Figure 4C).

The expression levels of these 27 genes were then evaluated in a complementary mouse allograft VGLL2-NCOA2 model and human VGLL2-NCOA2 tumors compared with mature skeletal muscle. Plotted is the fold change of these 27 genes in zebrafish relative to their expression in our mouse VGLL2-NCOA2 allograft model (Figure 4D) and in human VGLL2-NCOA2 tumors (Figure 4E). This allowed us to further refine our search for genes that are commonly dysregulated in all three VGLL2-NCOA2 contexts. Interestingly, although muscle regulatory factors were expressed in VGLL2-NCOA2 tumors, there was not a significant difference in the expression level compared with mature skeletal muscle or developmental samples (Figure S4A). Overall, this analysis identified genes with expression in tumors that more closely matched embryos rather than mature skeletal muscle, suggesting that VGLL2-NCOA2 could co-opt embryonic gene expression programs to promote tumor growth.

with mature skeletal muscle ( $n = 20$ ; NCBI BioProjects PRJNA625451,<sup>28</sup> PRJNA608179,<sup>29</sup> PRJNA819493, PRJNA813153<sup>30</sup>). If the gene is red, it is statistically significant, and, if it is blue, it is not statistically significant in the mouse context.

(E) Comparison of the expression of these 27 developmental genes in human VGLL2-NCOA2 tumors. Plotted is the fold change of these 27 genes in VGLL2-NCOA2 zebrafish tumors ( $n = 18$ ) compared with mature skeletal muscle ( $n = 7$ ), and in human VGLL2-NCOA2 tumors ( $n = 5$ ; Watson et al.<sup>4</sup>) compared with mature skeletal muscle ( $n = 803$ ; GTEx version 8). If the gene is red, it is statistically significant, and, if it is blue, it is not statistically significant in the human context. An FDR of 0.1 was used for genes to be included in the analysis in (D) and (E).





(legend on next page)

### Cross-species comparative oncology analysis identifies ARF6 as upregulated in zebrafish, mouse allograft, and human VGLL2-NCOA2 tumors

Gene ontology analysis of genes differentially expressed between VGLL2-NCOA2 zebrafish tumors and mature skeletal muscle highlighted several GTPases and their functions (Figure S4B). One of the genes significantly overexpressed in all three VGLL2-NCOA2 tumor contexts (zebrafish, mouse allograft, and human), as well as in development, was *arf6b*, a small GTPase involved in endocytosis and membrane receptor recycling and in actin reorganization (Figure 4C).<sup>31</sup> In zebrafish, the *arf6* gene is duplicated and is referred to as *arf6a* and *arf6b*. The zebrafish Arf6a and Arf6b protein sequences are identical and share 99% identity with the ARF6 human ortholog (Figure S4C). We performed qRT-PCR on both *arf6a* and *arf6b* to determine mRNA expression levels in an independent zebrafish tumor cohort, and found that *arf6a* was modestly elevated and *arf6b* was significantly elevated in development and tumor samples compared with mature skeletal muscle (Figure 5A). This pattern was even more striking at the protein level, where Arf6 protein expression was significantly upregulated in the context of VGLL2-NCOA2 tumors compared with embryos and mature skeletal muscle (Figures 5B and 5C). To verify the spatial expression of Arf6, we performed Arf6 immunohistochemistry on serial sections of zebrafish VGLL2-NCOA2 tumors and found that Arf6 protein expression overlaid with tumor cells and human anti-NCOA2 positive cells (Figure 5C). A control H&E and Arf6 IHC stain from a wild-type zebrafish transverse section is shown in Figure S4D, and the control anti-NCOA2 stain is shown in Figure 2A. These data suggest that Arf6 is highly expressed in VGLL2-NCOA2 established tumors and could be contributing to the disease process.

To implement a cross-species comparative oncology approach, we generated a C2C12 mouse myoblast cell line that constitutively and stably overexpressed the human form of the VGLL2-NCOA2 fusion that is used in our zebrafish models. We found that the fusion was highly expressed at the protein level even after passage and selection in culture (Figure 6A). Further, when either C2C12-pCDNA3.1 control or C2C12-VGLL2NCOA2 cells were allografted into severe combined immunodeficiency (SCID) or Nude mice, cells overexpressing the VGLL2-NCOA2 fusion generated aggressive tumors that rapidly grew with initial detection at 11 days post injection and termination of the experiment at 26–28 days post injection (Figures 6B and 6C). This indicates that the human form of the fusion oncogene is transforming in multiple systems.

On pathological analysis, C2C12-pCDNA3.1 control allografts resulted only in small lesions at the site of injection, composed of bland spindle cells (Figures 6D and S5A). Conversely, C2C12-VGLL2NCOA2 allografts consistently produced tumors showing features of high-grade sarcoma, with both spindle cell and pleomorphic morphology (Figures 6D; S5B). C2C12-VGLL2NCOA2 allografts also exhibited muscle invasion and tumor necrosis (Figures S5C–S5F). Further, C2C12-VGLL2NCOA2 allograft tumors expressed clinically diagnostic markers of infantile rhabdomyosarcoma, including heterogeneous expression of Desmin and Myogenin (Figure 6E; Table S4). The fusion-driven tumors also exhibited elevated staining for Ki67, suggesting an increase in proliferation compared with C2C12-pCDNA3.1 controls (Figure 6E). We performed RNA-seq on a subset of these generated C2C12-pCDNA3.1 control and C2C12-VGLL2NCOA2 allografts and compared their transcriptional profiles with that of the human disease, in a similar strategy that was used for zebrafish VGLL2-NCOA2 tumors. Using an AGDEX analysis, we found that our allograft C2C12-VGLL2NCOA2 model was consistent with the human disease, and shared 9,763 differentially expressed genes (Figure S6A). A UMAP analysis of transcriptional signatures shows that C2C12-VGLL2NCOA2 tumors cluster with human VGLL2-NCOA2 tumors, whereas C2C12-pCDNA3.1 controls cluster with mouse skeletal muscle (Figure S6B). We performed a gene set enrichment analysis of these 9,763 shared mouse and human differentially expressed genes, which revealed similarly regulated pathways as in our zebrafish model, including enrichment of extracellular matrix and suppression of skeletal muscle development (Figure S6C). In cell culture, C2C12-VGLL2NCOA2 exhibits an increase in H3K27 acetylation at the Arf6 promoter in the context of the fusion, and, in VGLL2-NCOA2 allograft tumors, *Arf6* was significantly overexpressed compared with controls (Figures S6D, 4D, and 6F). Further, we found evidence of Arf6 protein expression by immunohistochemistry in the C2C12-VGLL2NCOA2 allograft tumor models of the disease (Figure 6G; Table S4).

### Functional cooperation of VGLL2-NCOA2 and ARF6 for sarcomagenesis

Our cross-species comparative oncology approach identified ARF6 as a developmentally regulated gene that is highly expressed in VGLL2-NCOA2 tumors. Next, we wanted to evaluate the functional contribution of ARF6 to the disease process. To do this, we generated C2C12 Arf6 knockout clones using a CRISPR-Cas9 strategy with a guide targeting *Arf6*. These cells have a premature stop in Arf6 resulting in a 109-amino-acid protein product and no detectable protein expression (Figure 7A).


#### Figure 5. Zebrafish VGLL2-NCOA2 tumors express Arf6 protein

(A) qRT-PCR of *arf6a* and *arf6b* levels using an independent cohort of  $n = 6$  zebrafish tumors,  $n = 4$  zebrafish mature skeletal muscle samples, and  $n = 4$  pools of zebrafish embryos at a developmental time point of 20 h post fertilization. Each data point is an individual tumor or normal tissue sample. The error bars represent the mean  $\pm$  SD. The  $p$  values were calculated using a one-way ANOVA followed by Tukey's multiple comparisons post hoc test.

(B) Western blot for Arf6 protein. For each group, protein lysate was loaded from pools of developing wild-type embryos ( $n = 12$  embryos per pool) or 25  $\mu$ g of lysate from mature skeletal muscle or VGLL2-NCOA2 tumors. Loading consistency is verified by Coomassie staining. Quantification is performed by normalizing Arf6 to total protein as determined by Coomassie. Each plotted data point is a biological replicate. The error bars represent the mean  $\pm$  SD. The  $p$  values were calculated using a one-way ANOVA followed by Tukey's multiple comparisons post hoc test.

(C) Representative images of VGLL2-NCOA2 zebrafish tumors shown as brightfield overlaid with GFP fluorescence (scale bars, 2 mm), with serial transverse sections stained with H&E, an anti-NCOA2 antibody, and an anti-ARF6 antibody (scale bars, 500  $\mu$ m). All  $n = 8$  zebrafish tumors stained for Arf6 were positive.





(legend on next page)



We then expressed the human *VGLL2-NCOA2* construct using the pcDNA3.1 vector as described in Figure 6, and, after selection in culture, generated stable cell lines with or without Arf6 knockout or *VGLL2-NCOA2* expression (Figure 6A). First, we assessed whether the *VGLL2-NCOA2* fusion or Arf6 knockout had any impact on cellular proliferation, and found there was no difference across all groups (Figures S7A and S7B), suggesting an alternative mechanism for cooperation. Next, we assessed how the *VGLL2-NCOA2* fusion with or without Arf6 knockout affected the myogenic process. We seeded confluent C2C12 myoblasts onto porcine gelatin-coated dishes and serum starved them for 5 days after plating. C2C12 myoblasts should fuse into multinucleated myotubes that express myogenin (*MyoG*), an earlier fusion marker, and myosin light and heavy chain (*Myl1*, *Myh1*), more terminal markers of differentiation. We found that the *VGLL2-NCOA2* fusion significantly reduced the mRNA expression of *MyoG*, *Myl1*, and *Myh1* (Figures 7B, S7C, and S7D) by day 6 of fusion. However, Arf6 knockout mitigated this effect, restoring *MyoG*, *Myl1*, and *Myh1* expression levels and rescuing the overall morphology of the cells (Figures 7B, 7C, S7C, and S7D). These assays were complemented with a soft agar colony formation assay to determine the tumorigenic capacity of these cells in cultures. We seeded C2C12-*VGLL2NCOA2* or control with or without Arf6 knockout in soft agar and allowed colonies to develop for 2 weeks, after which they were counted. Shown are examples of colonies formed with each condition, with both C2C12 wild-type and Arf6 knockout transfected with control pcDNA3.1 empty plasmid failing to generate colonies (Figure 7D). Quantification of the number of colonies per well indicates that Arf6 knockout suppresses *VGLL2-NCOA2* transformation capacity by 2.8-fold (Figure 7E). Together, these data suggest that Arf6 is a genetic cooperating event in the disease and could be a potential therapeutic target.

Next, we analyzed RNA-seq data from patient tumors, and performed differential expression analysis between human *VGLL2-NCOA2* tumors and human mature skeletal muscle. We found that *ARF6* mRNA was modestly overexpressed in the human disease (Figures 4E and 7F). To more broadly assess the potential applicability of *ARF6* inhibition in sarcoma, we analyzed *ARF6* expression in a panel of sarcomas and found that this

observation may be translatable to many other sarcomas. There was similar overexpression of *ARF6* compared with mature skeletal muscle in adult sarcomas in general, and in pediatric sarcomas, including Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma. Notably, this did not hold true for clear cell sarcoma of kidney (Figure 7G).

Overall, development is a tightly controlled and orchestrated process involving appropriate gene activation and inactivation to dictate migration, cell division, and structure formation. Our data suggest that *VGLL2-NCOA2* is an oncogene that potentially leverages developmental programs in order to promote sarcomagenesis. There are two distinct, but not mutually exclusive, possibilities for the mechanism: one in which, during maturation, developmental genes continuously decrease in expression and are then reactivated either at the onset or during tumorigenesis. Alternatively, developmental genes may never decrease in expression and instead inappropriately persist throughout the course of tumorigenesis. Further studies will be required to delineate the mechanisms by which *VGLL2-NCOA2* mediates these changes in gene expression and their functional role in tumorigenesis.

## DISCUSSION

Each sarcoma gene fusion produces a slightly different disease that warrants the development of a genetic animal model system to understand the biology and to identify potential therapeutic targets. This is difficult to accomplish. Often, the sarcoma cell of origin is unknown, making screening putative cellular origins in mouse models costly and burdensome. Zebrafish complement mouse models as a timely approach to make significant contributions to understanding rare genetic diseases and pediatric cancer. Zebrafish capture a relevant developmental context and have conserved genetics and molecular signaling pathways.<sup>32–34</sup> By applying these models, one can complement clinical sequencing efforts and rapidly define the biology of identified gene fusions to determine the most significant features of the disease. Previously, we described a genetic approach focused on *PAX3-FOXO1* rhabdomyosarcoma and *CIC-DUX4* sarcoma transgenic zebrafish modeling.<sup>23,24</sup> We have now broadened

### Figure 6. *VGLL2-NCOA2* is transforming in mouse myoblast allograft models

(A) C2C12 mouse myoblasts transfected with human *VGLL2-NCOA2* express the *VGLL2-NCOA2* fusion protein 24 h post transfection and stably after passaging and selection in growth medium with G418 compared with a C2C12-pcDNA3.1 empty control.

(B) Allograft leg volume of C2C12-pcDNA3.1 control and C2C12-*VGLL2NCOA2* after intramuscular injection into the leg of SCID mice. C2C12-pcDNA3.1 control was injected in n = 10 allografts and C2C12-*VGLL2NCOA2* was injected in n = 6 allografts. The error bars represent the mean leg volume ± SEM. Error bars are not shown if it is within the boundaries of the symbol. Leg volume at time points were compared using a Mann-Whitney U test corrected for multiple comparisons using the Benjamini, Krieger, and Yekutieli method. \*p < 0.0005. Every time point after zero is statistically significant.


(C) Allograft leg volume of C2C12-pcDNA3.1 control and C2C12-*VGLL2NCOA2* after intramuscular injection into the leg of Swiss Nude mice. C2C12-pcDNA3.1 was injected in n = 10 allografts and C2C12-*VGLL2NCOA2* was injected in n = 6 allografts. The error bars represent the mean leg volume ± SEM. Error bars are not shown if they are within the boundaries of the symbol. Tumor volume at time points were compared using a Mann-Whitney U test corrected for multiple comparisons using the Benjamini, Krieger, and Yekutieli method. \*p < 0.0005. Every time point after zero is statistically significant.

(D) Representative hematoxylin-eosin saffron (HES) staining from a C2C12-pcDNA3.1 control allograft and a C2C12-*VGLL2NCOA2* tumor allograft. Scale bars, 50 μm.

(E) Representative immunohistochemistry for Desmin, Myogenin, and Ki67 for C2C12-pcDNA3.1 control allograft and a C2C12-*VGLL2NCOA2* tumor allograft. Scale bars, 50 μm.

(F) *Arf6* mRNA levels from RNA-seq of allografts from Swiss Nude mice, including two C2C12-pcDNA3.1 controls and six C2C12-*VGLL2NCOA2* tumors. Error bars represent mean ± SD. *Arf6* mRNA expression was compared using a Welch's t test.

(G) Representative immunohistochemistry for Arf6 protein levels in C2C12-pcDNA3.1 controls and C2C12-*VGLL2NCOA2* tumors. Eleven C2C12-pcDNA3.1 controls and six C2C12-*VGLL2NCOA2* tumor samples were analyzed. Results are presented in Table S4. Scale bars, 50 μm.



**Figure 7. Genetic cooperation of VGLL2-NCOA2 and ARF6 for sarcomagenesis**

(A) Monoclonal C2C12 populations with stable Arf6 knockout were generated with CRISPR-Cas9 and guides targeting *Arf6*. Wild-type or Arf6 knockout cells were transfected with pcDNA3.1 empty control or pcDNA3.1 expressing VGLL2-NCOA2 under control of the CMV promoter. Shown is a western blot of generated C2C12 cell lines indicating VGLL2-NCOA2 fusion expression, Arf6 expression, and Tubulin as a loading control.

(B) qRT-PCR for *Myh1* expression relative to loading controls, *Gapdh* and *Rpl27*, for days 0, 2, and 6 of myogenic fusion. Each data point is a biological replicate. The error bars represent the mean  $\pm$  SD. The p values were calculated using a one-way ANOVA followed by Tukey's multiple comparisons post hoc test. This was repeated once.

(legend continued on next page)

our approach to incorporate additional rhabdomyosarcoma fusion oncogenes. This modular platform can be implemented for any rhabdomyosarcoma fusion identified from clinical sequencing efforts that has yet to be studied in a laboratory setting.

Here, we applied this strategy to demonstrate that *VGLL2-NCOA2* is an oncogene that generates sarcoma in genetic zebrafish and mouse allograft systems. When the human form of the fusion is integrated into the zebrafish genome, zebrafish develop tumors that are histologically and molecularly consistent with the human disease. Introduction of the *VGLL2-NCOA2* fusion into C2C12 mouse myoblasts and allografts of these models result in aggressive tumors by 3 weeks post injection. These data indicate the fusion alone is sufficient for transformation and does not require cooperating events. This highlights the capacity of the zebrafish system to faithfully capture distinct sarcoma subtypes based on the driving oncogene. For example, zebrafish *VGLL2-NCOA2* tumors present at a much earlier age and have distinct histology and unique gene expression profiles compared with our *PAX3-FOXO1* zebrafish tumor model.<sup>23</sup> This is consistent with the human disease, in which patients with *VGLL2-NCOA2* tumors present between 0 and 1 year with distinct histology from *PAX3-FOXO1*-driven rhabdomyosarcoma. The CMV promoter efficiently generated *VGLL2-NCOA2* tumors in our zebrafish and mouse models and drove high expression levels of *VGLL2-NCOA2*, resulting in the aggressive pathology and higher levels of expression than is observed in the human disease (data not shown). However, the molecular features and general pathology are consistent, but this opens the possibility that utilizing more nuanced promoters could reflect the heterogeneity observed in the human disease. Our data underscore the importance of creating and studying animal models of rare genetic diseases to determine biological differences and similarities in pediatric sarcomas.

In infantile rhabdomyosarcoma, there are other fusion partners for *VGLL2*, including *CITED2*.<sup>4,8,18,20</sup> However, transcriptional clustering indicates *VGLL2*-fused tumors have shared signatures, suggesting that *VGLL2* and its regulatory elements are the predominant drivers for this disease.<sup>4,20</sup> Insight into normal *VGLL2* expression and its targets may help understand its activity in the fusion. *VGLL2* is highly expressed during mouse embryonic development in the somitic myotome and pharyngeal pouch, but, in adult tissues, its expression is restricted to skeletal muscle.<sup>35</sup> In human development, *VGLL2* is solely expressed in fetal skeletal muscle, and is absent from cardiac, liver, thymus, or brain.<sup>35</sup> This specific expression and interaction partners

could explain the immature muscle features of the disease. A *Vgll2* knockout mouse has helped elucidate its role in skeletal muscle development, and *Vgll2* knockout mice exhibit defects in skeletal muscle fiber type composition and exercise exhaustion.<sup>36,37</sup> This model has confirmed direct interaction with *Vgll2* and *Tead1/4* by co-immunoprecipitation in embryonic skeletal muscle.<sup>36</sup> Intriguingly, *TEAD1-NCOA2* fusions are another defining genetic event in congenital sarcoma with a similar clinical presentation.<sup>18,19</sup> Perhaps *VGLL2* is responsible for regulating targets through *TEAD1/4* proteins for precise developmental control, and this could be co-opted or deregulated by the *VGLL2-NCOA2* fusion.

Transcriptional analysis of *VGLL2-NCOA2* zebrafish tumors identified a subset that clustered with somitogenesis in the developing zebrafish, distinct from zebrafish mature skeletal muscle. These results suggest that tumor programs either reactivate developmental genes or that developmental genes inappropriately persist. Our differential gene expression analysis highlighted small GTPases in zebrafish, mouse allograft, and human *VGLL2-NCOA2* tumor samples. Specifically, of these GTPases, *Arf6* had increased protein expression in zebrafish tumors and was completely absent in mature skeletal muscle. The sufficiency of the *VGLL2-NCOA2* fusion and overexpression of *Arf6* in the context of the fusion was confirmed in C2C12 mouse allograft models. In the human disease, *ARF6* mRNA is overexpressed in *VGLL2-NCOA2* patient tumors compared with mature skeletal muscle. Our functional analyses indicate that *ARF6* and *VGLL2-NCOA2* genetically cooperate to inhibit the skeletal muscle differentiation process and suppress colony formation *in vitro*. More broadly, in a panel of pediatric and adult sarcomas, *ARF6* is overexpressed compared with mature skeletal muscle, suggesting that *ARF6* could be a potential therapeutic target in many sarcoma contexts. Perhaps this has been overlooked because *ARF6* mRNA levels do not always correlate with *ARF6* protein expression (Figures 5A–5C),<sup>38</sup> and *ARF6* is not a defining feature of any sarcoma subtype but represents a shared feature of the disease.

*ARF6* is a highly conserved mediator of developmental processes, myogenesis, and carcinogenesis, all of which could contribute to its function in *VGLL2-NCOA2* tumors. Studies in sea urchins suggest that *Arf6* knockdown impairs gastrulation and alters directed migration of primary mesenchyme cells.<sup>39</sup> This is complemented from data in *Arf6* null mice, which are embryonic lethal indicating a critical developmental role.<sup>40</sup> *ARF6* is also a core member of the complex required for myoblast fusion and muscle development.<sup>41</sup> Impaired muscle differentiation is a hallmark of rhabdomyosarcoma, and these

(C) Representative brightfield images of myotube morphology taken on day 6 of fusion for each treatment group. Scale bar, 100  $\mu$ m.

(D) Representative brightfield images of colonies in soft agar taken on day 14 post plating for each treatment group. Scale bar, 100  $\mu$ m.

(E) Quantification of the number of colonies per well on a six-well plate. Each data point is a biological replicate. The error bars represent the mean  $\pm$  SD. The p values were calculated using a one-way ANOVA followed by Tukey's multiple comparisons post hoc test. This was repeated twice.

(F) *ARF6* expression determined by RNA-seq in human mature skeletal muscle (n = 396; GTEX) and *VGLL2-NCOA2* tumors from Watson et al.<sup>4</sup> (n = 5; one is a primary and recurrent from the same patient). Each data point is an individual tumor or normal tissue sample. The error bars represent the mean  $\pm$  SD. The p values were calculated using the Mann-Whitney U test.

(G) *ARF6* expression from (F) and compared with additional sarcoma tumor samples, including adult sarcoma from The Cancer Genome Atlas (TCGA) (n = 264), clear cell sarcoma of kidney (n = 13), Ewing sarcoma (n = 95), osteosarcoma (n = 87), and rhabdomyosarcoma (n = 42). Each data point is an individual tumor or normal tissue sample. The error bars represent the mean  $\pm$  SD. The p values were calculated using the Mann-Whitney U test and are a comparison of each tumor cohort with skeletal muscle.



processes are aberrant in VGLL2-NCOA2 tumors, which express the early markers of myogenesis but appear histologically undifferentiated. ARF6 activation or overexpression has a role in other cancer contexts and promotes proliferation, invasion, and metastasis or predicts poor prognosis in breast cancer, melanoma, lung cancer, and other solid tumors.<sup>38,42–46</sup> A remaining question is the contribution of ARF6 to tumor initiation versus maintenance (or both), which is not clear and will be a focus of future lines of research. ARF6 has also been proposed as a therapeutic opportunity in cancer.<sup>47</sup> In uveal melanoma, an ARF6 inhibitor, NAV-2729 inhibited tumor growth in xenograft models of the disease.<sup>43</sup> Although ARF6 is broadly expressed, the tolerability of NAV-2729 in these studies indicates that there may be a therapeutic window. Whether this is true in VGLL2-NCOA2-driven rhabdomyosarcoma, or sarcoma in general, remains to be seen.

Overall, we developed transgenic zebrafish and mouse allograft models of VGLL2-NCOA2 fusion-driven sarcoma and our cross-species comparative oncology approach identified a potential therapeutic opportunity, ARF6. Our findings also highlight how studying rare disease can illuminate molecular mechanisms or systems that are more broadly applicable. We have now presented a strategy for building fusion-oncogene-driven animal models to define biology, identify therapeutic opportunities, and intersect data to determine conserved sarcoma disease drivers.

### Limitations of the study

Our findings demonstrate a conserved role for the human VGLL2-NCOA2 fusion oncogenic function in zebrafish and mouse allograft models of the disease. We utilized the CMV promoter to generate these models, which drives high levels of expression of the VGLL2-NCOA2 fusion. Although the CMV promoter driving VGLL2-NCOA2 generated tumors that recapitulate the human disease, a more nuanced approach would involve restricting the expression of the fusion to various cell lineages to determine their capacity for transformation. Such approaches could better reflect the heterogeneity that is observed in the human disease.

Further, integration of transcriptional data from our VGLL2-NCOA2 zebrafish and mouse allograft models with patient tumor data identified overexpression of ARF6 as a shared disease feature. To investigate the role of ARF6 in the disease, we generated a C2C12 Arf6 CRISPR-Cas9 knockout cell line. However, the Arf6 cell knockouts that were generated only address the role of Arf6 in tumor initiation and transformation events. The long-term goal is to understand Arf6 therapeutically, which will require temporal control of knockdown during different stages of tumorigenesis, or as a complementary approach, utilizing a small-molecule NAV-2729 Arf6 inhibitor.

### STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY

- Lead contact
- Materials availability
- Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Zebrafish
  - Mice
  - Cells
  - Human sarcoma and skeletal muscle samples
- METHOD DETAILS
  - Plasmids and cloning
  - Zebrafish embryo injections
  - Zebrafish tumor collection and processing
  - Zebrafish tumor incidence
  - Generation of genetically modified C2C12 cell lines
  - Western blot
  - ChIP-qPCR
  - Mouse allograft experiments and tumor processing
  - *In situ* hybridization and immunofluorescence
  - Immunohistochemistry
  - Cellular proliferation of C2C12 *in vitro*
  - Myogenic differentiation of C2C12 *in vitro*
  - Soft agar colony formation
  - RNA isolation, RT-PCR and qRT-PCR
  - RNA sequencing and analysis
  - Comparative oncology RNA-seq analysis
  - Human sarcoma and skeletal muscle RNA-seq analysis
  - PCA of zebrafish tumors and developmental stages
  - Gene ontology analysis
- QUANTIFICATION AND STATISTICAL ANALYSIS

### SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.celrep.2023.112013>.

### ACKNOWLEDGMENTS

We thank the UT Southwestern Histopathology core for excellent services and for their expertise, and the Nationwide Children's Hospital (NCH) Animal Resources Core for their exceptional zebrafish husbandry. Additional support was provided by the Nationwide Children's Hospital Microscopy Lab in the Center for Gene Therapy for imaging, the NCH Morphology Core for tissue processing, the NCH CRISPR/Gene Editing Core for generating cell line knockouts, and the NCH High-Performance Computing group for assistance maintaining and using the NCH cluster. G.C.K. is supported by an Alex's Lemonade Stand Foundation A Award, a V Foundation for Cancer Research V Scholar Grant, and an R01CA272872 grant through the National Cancer Institute of the National Institutes of Health. J.F.A. was supported by grant RP120685-P3 from the Cancer Prevention and Research Institute of Texas (CPRIT) and by Curing Kids Cancer. L.X. is supported by Rally Foundation, Cancer Center Support Grant P30 CA142543 and RP180805 from CPRIT. F.T. is supported by the Institut National de la Recherche Médicale (INSERM). D.R. is supported by grant RP180319 from the Cancer Prevention and Research Institute of Texas (CPRIT) and by the John Lawrence and Patsy Louise Goforth Chair in Pathology. S.W. was supported by a grant from the Fondation Nuovo-Soldati pour la recherche en cancérologie. M.K. is supported by a T32CA269052 Training Program in Basic and Translational Pediatric Oncology Research postdoctoral fellowship. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

### AUTHOR CONTRIBUTIONS

S.W., F.T., O.D., J.F.A., and G.C.K. conceived and supervised the study. F.T. provided computational analysis, insight, and expertise of human and zebrafish RNA-seq data and their similarity in **Figures 2, 6, and S3**. L.X. provided computational analysis, insight, and expertise into developmental studies and human and zebrafish RNA-seq data in **Figures 3, 7, and S4**. M.V.C. provided computational analysis, insight, and expertise in **Figures 2, 4, S3, and S6**. D.R. and J.C. provided pathological assessment. S.W., C.A.L., D.S., J.C., D.C., M.K., K.S., J.K., E.H., W.M., and G.C.K. performed experiments. C.A.L., J.C., D.C., M.K., K.S., J.K., E.H., and G.C.K. analyzed experimental data. C.A.L., J.F.A., and G.C.K. drafted the manuscript and figures. All authors reviewed and edited the final manuscript.

### DECLARATION OF INTERESTS

The authors declare no competing interests.

### INCLUSION AND DIVERSITY

One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in their field of research or within their geographical location. One or more of the authors of this paper received support from a program designed to increase minority representation in their field of research. One or more of the authors of this paper self-identifies as living with a disability. We support inclusive, diverse, and equitable conduct of research.

Received: January 10, 2022

Revised: October 14, 2022

Accepted: January 4, 2023

### REFERENCES

- Mitelman, F., B. J., and Mertens, F. (2021). Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer. <https://mitelmandatabase.isb-cgc.org>.
- Mitelman, F., Johansson, B., and Mertens, F. (2007). The impact of translocations and gene fusions on cancer causation. *Nat. Rev. Cancer* 7, 233–245. <https://doi.org/10.1038/nrc2091>.
- Mertens, F., Antonescu, C.R., and Mitelman, F. (2016). Gene fusions in soft tissue tumors: recurrent and overlapping pathogenetic themes. *Genes Chromosomes Cancer* 55, 291–310. <https://doi.org/10.1002/gcc.22335>.
- Watson, S., Perrin, V., Guillemot, D., Reynaud, S., Coindre, J.M., Karanian, M., Guinebretière, J.M., Freneaux, P., Le Loarer, F., Bouvet, M., et al. (2018). Transcriptomic definition of molecular subgroups of small round cell sarcomas. *J. Pathol.* 245, 29–40. <https://doi.org/10.1002/path.5053>.
- Gröbner, S.N., Worst, B.C., Weischenfeldt, J., Buchhalter, I., Kleinheinz, K., Rudneva, V.A., Johann, P.D., Balasubramanian, G.P., Segura-Wang, M., Brabetz, S., et al. (2018). The landscape of genomic alterations across childhood cancers. *Nature* 555, 321–327. <https://doi.org/10.1038/nature25480>.
- Tirode, F., Surdez, D., Ma, X., Parker, M., Le Deley, M.C., Bahrami, A., Zhang, Z., Lapouble, E., Grossetête-Lalami, S., Rusch, M., et al. (2014). Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. *Cancer Discov.* 4, 1342–1353. <https://doi.org/10.1158/2159-8290.CD-14-0622>.
- Shern, J.F., Chen, L., Chmielecki, J., Wei, J.S., Patidar, R., Rosenberg, M., Ambrogio, L., Auclair, D., Wang, J., Song, Y.K., et al. (2014). Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. *Cancer Discov.* 4, 216–231. <https://doi.org/10.1158/2159-8290.CD-13-0639>.
- Alaggio, R., Zhang, L., Sung, Y.S., Huang, S.C., Chen, C.L., Bisogno, G., Zin, A., Agaram, N.P., LaQuaglia, M.P., Wexler, L.H., and Antonescu, C.R. (2016). A molecular study of pediatric spindle and sclerosing rhabdomyosarcoma: identification of novel and recurrent VGLL2-related fusions in infantile cases. *Am. J. Surg. Pathol.* 40, 224–235. <https://doi.org/10.1097/PAS.0000000000000538>.
- Günther, S., Mielcarek, M., Krüger, M., and Braun, T. (2004). VITO-1 is an essential cofactor of TEF1-dependent muscle-specific gene regulation. *Nucleic Acids Res.* 32, 791–802. <https://doi.org/10.1093/nar/gkh248>.
- Maeda, T., Chapman, D.L., and Stewart, A.F.R. (2002). Mammalian vestigial-like 2, a cofactor of TEF-1 and MEF2 transcription factors that promotes skeletal muscle differentiation. *J. Biol. Chem.* 277, 48889–48898. <https://doi.org/10.1074/jbc.M206858200>.
- Pobbati, A.V., and Hong, W. (2013). Emerging roles of TEAD transcription factors and its coactivators in cancers. *Cancer Biol. Ther.* 14, 390–398. <https://doi.org/10.4161/cbt.23788>.
- Johnson, C.W., Hernandez-Lagunas, L., Feng, W., Melvin, V.S., Williams, T., and Artinger, K.B. (2011). Vgll2a is required for neural crest cell survival during zebrafish craniofacial development. *Dev. Biol.* 357, 269–281. <https://doi.org/10.1016/j.ydbio.2011.06.034>.
- Wang, L., Motoi, T., Khanin, R., Olshen, A., Mertens, F., Bridge, J., Dal Cin, P., Antonescu, C.R., Singer, S., Hameed, M., et al. (2012). Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. *Genes Chromosomes Cancer* 51, 127–139. <https://doi.org/10.1002/gcc.20937>.
- Sumegi, J., Streblov, R., Frayer, R.W., Dal Cin, P., Rosenberg, A., Meloni-Ehrig, A., and Bridge, J.A. (2010). Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family. *Genes Chromosomes Cancer* 49, 224–236. <https://doi.org/10.1002/gcc.20731>.
- Argani, P., Reuter, V.E., Kapur, P., Brown, J.E., Sung, Y.S., Zhang, L., Williamson, R., Francis, G., Somerville, S., Swanson, D., et al. (2018). Novel MEIS1-NCOA2 gene fusions define a distinct primitive spindle cell sarcoma of the kidney. *Am. J. Surg. Pathol.* 42, 1562–1570. <https://doi.org/10.1097/PAS.0000000000001140>.
- Kao, Y.C., Bennett, J.A., Suurmeijer, A.J.H., Dickson, B.C., Swanson, D., Wanjarí, P., Zhang, L., Lee, J.C., and Antonescu, C.R. (2021). Recurrent MEIS1-NCOA2/1 fusions in a subset of low-grade spindle cell sarcomas frequently involving the genitourinary and gynecologic tracts. *Mod. Pathol.* 34, 1203–1212. <https://doi.org/10.1038/s41379-021-00744-7>.
- Agaram, N.P., Zhang, L., Sung, Y.S., Cavalcanti, M.S., Torrence, D., Wexler, L., Francis, G., Somerville, S., Swanson, D., Dickson, B.C., et al. (2019). Expanding the spectrum of intraosseous rhabdomyosarcoma: correlation between 2 distinct gene fusions and phenotype. *Am. J. Surg. Pathol.* 43, 695–702. <https://doi.org/10.1097/PAS.0000000000001227>.
- Mosquera, J.M., Sboner, A., Zhang, L., Kitabayashi, N., Chen, C.L., Sung, Y.S., Wexler, L.H., LaQuaglia, M.P., Edelman, M., Sreekantaiah, C., et al. (2013). Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. *Genes Chromosomes Cancer* 52, 538–550. <https://doi.org/10.1002/gcc.22050>.
- Whittle, S.B., Hicks, M.J., Roy, A., Vasudevan, S.A., Reddy, K., and Venkatramani, R. (2019). Congenital spindle cell rhabdomyosarcoma. *Pediatr. Blood Cancer* 66, e27935. <https://doi.org/10.1002/pbc.27935>.
- Butel, T., Karanian, M., Pierron, G., Orbach, D., Ranchere, D., Cozic, N., Galmiche, L., Coulomb, A., Corradini, N., Lacour, B., et al. (2020). Integrative clinical and biopathology analyses to understand the clinical heterogeneity of infantile rhabdomyosarcoma: a report from the French MMT committee. *Cancer Med.* 9, 2698–2709. <https://doi.org/10.1002/cam4.2713>.
- Anderson, W.J., and Doyle, L.A. (2021). Updates from the 2020 world Health organization classification of soft tissue and bone tumours. *Histopathology* 78, 644–657. <https://doi.org/10.1111/his.14265>.
- Cyrta, J., Gauthier, A., Karanian, M., Vieira, A.F., Cardoen, L., Jehanno, N., Bouvet, M., Bouvier, C., Komuta, M., Le Loarer, F., et al. (2021). Infantile rhabdomyosarcomas with VGLL2 rearrangement are not always an indolent disease: a study of 4 aggressive cases with clinical, pathologic, molecular, and radiologic findings. *Am. J. Surg. Pathol.* 45, 854–867, Publish Ahead of Print. <https://doi.org/10.1097/pas.0000000000001702>.

23. Kendall, G.C., Watson, S., Xu, L., LaVigne, C.A., Murchison, W., Rakheja, D., Skapek, S.X., Tirode, F., Delattre, O., and Amatruda, J.F. (2018). PAX3-FOXO1 transgenic zebrafish models identify HES3 as a mediator of rhabdomyosarcoma tumorigenesis. *Elife* 7, e33800. <https://doi.org/10.7554/eLife.33800>.
24. Watson, S., Kendall, G.C., Rakheja, D., McFaul, M.E., Draper, B.W., Tirode, F., Delattre, O., and Amatruda, J.F. (2019). CIC-DUX4 expression drives the development of small round cell sarcoma in transgenic zebrafish: a new model revealing a role for ETV4 in CIC-mediated sarcomagenesis. Preprint at bioRxiv, 517722. <https://doi.org/10.1101/517722>.
25. Urasaki, A., Morvan, G., and Kawakami, K. (2006). Functional dissection of the Tol2 transposable element identified the minimal cis-sequence and a highly repetitive sequence in the subterminal region essential for transposition. *Genetics* 174, 639–649. <https://doi.org/10.1534/genetics.106.060244>.
26. White, R.J., Collins, J.E., Sealy, I.M., Wali, N., Dooley, C.M., Digby, Z., Stemple, D.L., Murphy, D.N., Billis, K., Hourlier, T., et al. (2017). A high-resolution mRNA expression time course of embryonic development in zebrafish. *Elife* 6, e30860. <https://doi.org/10.7554/eLife.30860>.
27. Pounds, S., Gao, C.L., Johnson, R.A., Wright, K.D., Poppleton, H., Finkelstein, D., Leary, S.E.S., and Gilbertson, R.J. (2011). A procedure to statistically evaluate agreement of differential expression for cross-species genomics. *Bioinformatics* 27, 2098–2103. <https://doi.org/10.1093/bioinformatics/btr362>.
28. Tanner, M.K., Tang, Z., and Thornton, C.A. (2021). Targeted splice sequencing reveals RNA toxicity and therapeutic response in myotonic dystrophy. *Nucleic Acids Res.* 49, 2240–2254. <https://doi.org/10.1093/nar/gkab022>.
29. Chakraborty, N., Waning, D.L., Gautam, A., Hoke, A., Sowe, B., Yousef, D., Butler, S., Savaglio, M., Childress, P.J., Kumar, R., et al. (2020). Genemetabolite Network linked to inhibited bioenergetics in association with spaceflight-induced loss of male mouse quadriceps muscle. *J. Bone Miner. Res.* 35, 2049–2057. <https://doi.org/10.1002/jbmr.4102>.
30. Mao, F., Wang, E., Xu, J., Lu, J., Yan, G., Fu, L., Jiao, Y., Wu, L., Liu, T., and Li, Y. (2022). Transcriptome analysis of multiple metabolic tissues in high-salt diet-fed mice. *Front. Endocrinol.* 13, 887843. <https://doi.org/10.3389/fendo.2022.887843>.
31. Donaldson, J.G. (2003). Multiple roles for Arf6: sorting, structuring, and signaling at the plasma membrane. *J. Biol. Chem.* 278, 41573–41576. <https://doi.org/10.1074/jbc.R300026200>.
32. Howe, K., Clark, M.D., Torroja, C.F., Torrance, J., Berthelot, C., Muffato, M., Collins, J.E., Humphray, S., McLaren, K., Matthews, L., et al. (2013). The zebrafish reference genome sequence and its relationship to the human genome. *Nature* 496, 498–503. <https://doi.org/10.1038/nature12111>.
33. McConnell, A.M., Noonan, H.R., and Zon, L.I. (2021). Reeling in the zebrafish cancer models. *Annu. Rev. Cancer Biol.* 5, 331–350. <https://doi.org/10.1146/annurev-cancerbio-051320-014135>.
34. Amatruda, J.F. (2021). Modeling the developmental origins of pediatric cancer to improve patient outcomes. *Dis. Model. Mech.* 14, dmm048930. <https://doi.org/10.1242/dmm.048930>.
35. Mielcarek, M., Günther, S., Krüger, M., and Braun, T. (2002). VITO-1, a novel vestigial related protein is predominantly expressed in the skeletal muscle lineage. *Mech. Dev.* 119, S269–S274. [https://doi.org/10.1016/S0925-4773\(03\)00127-8](https://doi.org/10.1016/S0925-4773(03)00127-8).
36. Honda, M., Hidaka, K., Fukada, S.I., Sugawa, R., Shirai, M., Ikawa, M., and Morisaki, T. (2017). Vestigial-like 2 contributes to normal muscle fiber type distribution in mice. *Sci. Rep.* 7, 7168. <https://doi.org/10.1038/s41598-017-07149-0>.
37. Honda, M., Tsuchimochi, H., Hitachi, K., and Ohno, S. (2019). Transcriptional cofactor Vgll2 is required for functional adaptations of skeletal muscle induced by chronic overload. *J. Cell. Physiol.* 234, 15809–15824. <https://doi.org/10.1002/jcp.28239>.
38. Hashimoto, S., Onodera, Y., Hashimoto, A., Tanaka, M., Hamaguchi, M., Yamada, A., and Sabe, H. (2004). Requirement for Arf6 in breast cancer invasive activities. *Proc. Natl. Acad. Sci. USA* 101, 6647–6652. <https://doi.org/10.1073/pnas.0401753101>.
39. Stepicheva, N.A., Dumas, M., Kobi, P., Donaldson, J.G., and Song, J.L. (2017). The small GTPase Arf6 regulates sea urchin morphogenesis. *Differentiation* 95, 31–43. <https://doi.org/10.1016/j.diff.2017.01.003>.
40. Suzuki, T., Kanai, Y., Hara, T., Sasaki, J., Sasaki, T., Kohara, M., Maehama, T., Taya, C., Shitara, H., Yonekawa, H., et al. (2006). Crucial role of the small GTPase ARF6 in hepatic cord formation during liver development. *Mol. Cell Biol.* 26, 6149–6156. <https://doi.org/10.1128/MCB.00298-06>.
41. Chen, E.H., Pryce, B.A., Tzeng, J.A., Gonzalez, G.A., and Olson, E.N. (2003). Control of myoblast fusion by a guanine nucleotide exchange factor, Ioner, and its effector ARF6. *Cell* 114, 751–762. [https://doi.org/10.1016/S0092-8674\(03\)00720-7](https://doi.org/10.1016/S0092-8674(03)00720-7).
42. Morishige, M., Hashimoto, S., Ogawa, E., Toda, Y., Kotani, H., Hirose, M., Wei, S., Hashimoto, A., Yamada, A., Yano, H., et al. (2008). GEP100 links epidermal growth factor receptor signalling to Arf6 activation to induce breast cancer invasion. *Nat. Cell Biol.* 10, 85–92. <https://doi.org/10.1038/ncb1672>.
43. Yoo, J.H., Shi, D.S., Grossmann, A.H., Sorensen, L.K., Tong, Z., Mleynek, T.M., Rogers, A., Zhu, W., Richards, J.R., Winter, J.M., et al. (2016). ARF6 is an actionable node that orchestrates oncogenic GNAQ signaling in uveal melanoma. *Cancer Cell* 29, 889–904. <https://doi.org/10.1016/j.ccell.2016.04.015>.
44. Yoo, J.H., Brady, S.W., Acosta-Alvarez, L., Rogers, A., Peng, J., Sorensen, L.K., Wolff, R.K., Mleynek, T., Shin, D., Rich, C.P., et al. (2019). The small GTPase ARF6 activates PI3K in melanoma to induce a prometastatic state. *Cancer Res.* 79, 2892–2908. <https://doi.org/10.1158/0008-5472.CAN-18-3026>.
45. Oka, S., Uramoto, H., Shimokawa, H., Yamada, S., and Tanaka, F. (2014). Epidermal growth factor receptor-GEP100-Arf6 axis affects the prognosis of lung adenocarcinoma. *Oncology* 86, 263–270. <https://doi.org/10.1159/000360089>.
46. Hashimoto, S., Mikami, S., Sugino, H., Yoshikawa, A., Hashimoto, A., Onodera, Y., Furukawa, S., Handa, H., Oikawa, T., Okada, Y., et al. (2016). Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer. *Nat. Commun.* 7, 10656. <https://doi.org/10.1038/ncomms10656>.
47. Yamauchi, Y., Miura, Y., and Kanaho, Y. (2017). Machineries regulating the activity of the small GTPase Arf6 in cancer cells are potential targets for developing innovative anti-cancer drugs. *Adv. Biol. Regul.* 63, 115–121. <https://doi.org/10.1016/j.jbior.2016.10.004>.
48. Ignatius, M.S., Hayes, M.N., Moore, F.E., Tang, Q., Garcia, S.P., Blackburn, P.R., Baxi, K., Wang, L., Jin, A., Ramakrishnan, A., et al. (2018). tp53 deficiency causes a wide tumor spectrum and increases embryonal rhabdomyosarcoma metastasis in zebrafish. *Elife* 7, e37202. <https://doi.org/10.7554/eLife.37202>.
49. Cancer Genome Atlas Research Network Electronic address elizabethdemico@sinaihhealthsystemca; Cancer Genome Atlas Research Network (2017). Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. *Cell* 171, 950–965.e28. <https://doi.org/10.1016/j.cell.2017.10.014>.
50. Crompton, B.D., Stewart, C., Taylor-Weiner, A., Alexe, G., Kurek, K.C., Calicchio, M.L., Kiezun, A., Carter, S.L., Shukla, S.A., Mehta, S.S., et al. (2014). The genomic landscape of pediatric Ewing sarcoma. *Cancer Discov.* 4, 1326–1341. <https://doi.org/10.1158/2159-8290.CD-13-1037>.
51. Chen, X., Stewart, E., Shelat, A.A., Qu, C., Bahrami, A., Hatley, M., Wu, G., Bradley, C., McEvoy, J., Pappo, A., et al. (2013). Targeting oxidative stress in embryonal rhabdomyosarcoma. *Cancer Cell* 24, 710–724. <https://doi.org/10.1016/j.ccr.2013.11.002>.
52. Berghmans, S., Murphey, R.D., Wienholds, E., Neuberg, D., Kutok, J.L., Fletcher, C.D.M., Morris, J.P., Liu, T.X., Schulte-Merker, S., Kanki, J.P., et al. (2005). tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors. *Proc. Natl. Acad. Sci. USA* 102, 407–412. <https://doi.org/10.1073/pnas.0406252102>.



53. Kwan, K.M., Fujimoto, E., Grabher, C., Mangum, B.D., Hardy, M.E., Campbell, D.S., Parant, J.M., Yost, H.J., Kanki, J.P., and Chien, C.B. (2007). The Tol2kit: a multisite gateway-based construction kit for Tol2 transposon transgenesis constructs. *Dev. Dyn.* 236, 3088–3099. <https://doi.org/10.1002/dvdy.21343>.
54. Mosimann, C., Kaufman, C.K., Li, P., Pugach, E.K., Tamplin, O.J., and Zon, L.I. (2011). Ubiquitous transgene expression and Cre-based recombination driven by the ubiquitin promoter in zebrafish. *Development* 138, 169–177. <https://doi.org/10.1242/dev.059345>.
55. Berger, J., and Currie, P.D. (2013). 503unc, a small and muscle-specific zebrafish promoter. *Genesis* 51, 443–447. <https://doi.org/10.1002/dvg.22385>.
56. Kawakami, K., Takeda, H., Kawakami, N., Kobayashi, M., Matsuda, N., and Mishina, M. (2004). A transposon-mediated gene trap approach identifies developmentally regulated genes in zebrafish. *Dev. Cell* 7, 133–144. <https://doi.org/10.1016/j.devcel.2004.06.005>.
57. Langmead, B., and Salzberg, S.L. (2012). Fast gapped-read alignment with Bowtie 2. *Nat. Methods* 9, 357–359. <https://doi.org/10.1038/nmeth.1923>.
58. Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 29, 15–21. <https://doi.org/10.1093/bioinformatics/bts635>.
59. Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., and Durbin, R.; 1000 Genome Project Data Processing Subgroup (2009). The sequence alignment/map format and SAMtools. *Bioinformatics* 25, 2078–2079. <https://doi.org/10.1093/bioinformatics/btp352>.
60. Anders, S., Pyl, P.T., and Huber, W. (2015). HTSeq—a Python framework to work with high-throughput sequencing data. *Bioinformatics* 31, 166–169. <https://doi.org/10.1093/bioinformatics/btu638>.
61. Gentleman, R.C., Carey, V.J., Bates, D.M., Bolstad, B., Dettling, M., Duodoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004). Bioconductor: open software development for computational biology and bioinformatics. *Genome Biol.* 5, R80. <https://doi.org/10.1186/gb-2004-5-10-r80>.
62. McCarthy, D.J., Chen, Y., and Smyth, G.K. (2012). Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. *Nucleic Acids Res.* 40, 4288–4297. <https://doi.org/10.1093/nar/gks042>.
63. Robinson, M.D., McCarthy, D.J., and Smyth, G.K. (2010). edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* 26, 139–140. <https://doi.org/10.1093/bioinformatics/btp616>.
64. Bray, N.L., Pimentel, H., Melsted, P., and Pachter, L. (2016). Near-optimal probabilistic RNA-seq quantification. *Nat. Biotechnol.* 34, 525–527. <https://doi.org/10.1038/nbt.3519>.
65. Zhang, Y., Parmigiani, G., and Johnson, W.E. (2020). ComBat-seq: batch effect adjustment for RNA-seq count data. *NAR Genom. Bioinform.* 2, lqaa078. <https://doi.org/10.1093/nargab/lqaa078>.
66. Huang, D.W., Sherman, B.T., and Lempicki, R.A. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat. Protoc.* 4, 44–57. <https://doi.org/10.1038/nprot.2008.211>.
67. Huang, D.W., Sherman, B.T., and Lempicki, R.A. (2009). Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res.* 37, 1–13. <https://doi.org/10.1093/nar/gkn923>.
68. Wu, T., Hu, E., Xu, S., Chen, M., Guo, P., Dai, Z., Feng, T., Zhou, L., Tang, W., Zhan, L., et al. (2021). clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. *Innovation* 2, 100141. <https://doi.org/10.1016/j.xinn.2021.100141>.
69. Yu, G., Wang, L.G., Han, Y., and He, Q.Y. (2012). clusterProfiler: an R package for comparing biological themes among gene clusters. *OMICS* 16, 284–287. <https://doi.org/10.1089/omi.2011.0118>.
70. Kendall, G.C., and Amatruda, J.F. (2016). Zebrafish as a model for the study of solid malignancies. *Methods Mol. Biol.* 1451, 121–142. [https://doi.org/10.1007/978-1-4939-3771-4\\_9](https://doi.org/10.1007/978-1-4939-3771-4_9).
71. Provost, E., Rhee, J., and Leach, S.D. (2007). Viral 2A peptides allow expression of multiple proteins from a single ORF in transgenic zebrafish embryos. *Genesis* 45, 625–629. <https://doi.org/10.1002/dvg.20338>.
72. Manoli, M., and Driever, W. (2012). Fluorescence-activated cell sorting (FACS) of fluorescently tagged cells from zebrafish larvae for RNA isolation. *Cold Spring Harb. Protoc.* 2012, pdb.prot069633. <https://doi.org/10.1101/pdb.prot069633>.
73. Sunkel, B.D., Wang, M., LaHaye, S., Kelly, B.J., Fitch, J.R., Barr, F.G., White, P., and Stanton, B.Z. (2021). Evidence of pioneer factor activity of an oncogenic fusion transcription factor. *iScience* 24, 102867. <https://doi.org/10.1016/j.isci.2021.102867>.
74. Borowicz, S., Van Scoyk, M., Avasarala, S., Karuppusamy Rathinam, M.K., Tauler, J., Bikkavilli, R.K., and Winn, R.A. (2014). The soft agar colony formation assay. *J. Vis. Exp.*, e51998. <https://doi.org/10.3791/51998>.
75. Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y., and Morishima, K. (2017). KEGG: new perspectives on genomes, pathways, diseases and drugs. *Nucleic Acids Res.* 45, D353–D361. <https://doi.org/10.1093/nar/gkw1092>.
76. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and Mesirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. USA* 102, 15545–15550. <https://doi.org/10.1073/pnas.0506580102>.
77. Mootha, V.K., Lindgren, C.M., Eriksson, K.F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003). PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nat. Genet.* 34, 267–273. <https://doi.org/10.1038/ng1180>.

STAR★METHODS

KEY RESOURCES TABLE

| REAGENT or RESOURCE                                      | SOURCE                  | IDENTIFIER                       |
|--|-------------------------|----------------------------------|
| <b>Antibodies</b>  |                         |                                  |
| Rabbit polyclonal anti-KAT13C/NCOA2                      | Abcam                   | Cat# ab10508; RRID:AB_297249     |
| Monoclonal mouse anti-beta actin, clone AC-74            | Sigma-Aldrich           | Cat# A5316; RRID:AB_476743       |
| Goat Anti-Rabbit IgG (H + L)-HRP Conjugate               | Bio-Rad                 | Cat# 1706515; RRID:AB_11125142   |
| Goat Anti-Mouse IgG (H + L)-HRP Conjugate                | Bio-Rad                 | Cat# 1706516; RRID:AB_11125547   |
| $\alpha$ -Tubulin (DM1A) Mouse mAb                       | Cell Signaling          | Cat# 3873; RRID:AB_1904178       |
| Rabbit polyclonal anti-ARF6 antibody                     | Abcam                   | Cat# ab226389                    |
| Histone H3K27ac antibody (pAb)                           | Active Motif            | Cat# 39133; RRID:AB_2561016      |
| Opal 520   | Fisher Scientific       | Cat# NC1601877                   |
| Anti-PCNA Antibody, clone PC10                           | Sigma-Aldrich           | Cat# MABE288; RRID:AB_11203836   |
| Cy3 AffiniPure Donkey Anti-Mouse IgG (H + L)             | Jackson ImmunoResearch  | Cat# 715165150; RRID:AB_2340813  |
| Polyclonal rabbit anti-NCOA2 antibody                    | Novus BIO               | Cat# NB100-1756; RRID:AB_2150934 |
| ARF6 antibody  | Abcam                   | Cat# ab77581; RRID:AB_2058475    |
| Monoclonal Mouse Anti-Desmin, Clone D33                  | Agilent Dako            | Cat# M0760; RRID:AB_2335684      |
| FLEX Monoclonal Mouse anti-Myogenin, Clone F5D           | Agilent Dako            | Cat# GA067; RRID:AB_2250893      |
| Recombinant Anti-Ki67 antibody (SP6)                     | Abcam                   | Cat# ab16667; RRID:AB_302459     |
| ARF6 Antibody (9E7T9)                                    | Novus BIO               | Cat# NBP3-15391                  |
| <b>Chemicals, peptides, and recombinant proteins</b>     |                         |                                  |
| Cytiva HyClone High Glucose DMEM                         | Fisher Scientific       | Cat# SH3002201                   |
| Gibco DMEM, high glucose, pyruvate                       | Fisher Scientific       | Cat# 11-995-065                  |
| Alt-R S.p. HiFi Cas9 Nuclease V3                         | IDT                     | Cat# 1081061                     |
| Alt-R Cas9 Electroporation Enhancer                      | IDT                     | Cat# 1075916                     |
| Gibco Geneticin Selective Antibiotic (G418 Sulfate)      | ThermoFisher Scientific | Cat# 10131035                    |
| GenJet In Vitro DNA Transfection Reagent for C2C12 Cells | SignaGen Laboratories   | Cat# SL100489-C2C12              |
| Roche cOMplete Protease Inhibitor Cocktail               | Sigma-Aldrich           | Cat# 11836145001                 |
| Halt Protease and Phosphatase Inhibitor Cocktail         | ThermoFisher Scientific | Cat# 78446                       |
| RIPA Buffer  | Sigma-Aldrich           | Cat# R0278                       |
| SuperSignal West Pico PLUS Chemiluminescent Substrate    | ThermoFisher Scientific | Cat# 34577                       |
| T-PER Tissue Protein Extraction Reagent                  | ThermoFisher Scientific | Cat# 78510                       |
| QC Colloidal Coomassie                                   | Bio-Rad                 | Cat# 1610803                     |
| iTaq Universal SYBR Green Supermix                       | Bio-Rad                 | Cat# 1725122                     |
| Invitrogen Prolong Gold Antifade with DAPI               | Fisher Scientific       | Cat# P36935                      |
| 3,3'-Diaminobenzidine tetrahydrochloride (DAB)           | Sigma-Aldrich           | Cat# D5905                       |
| Thermo Scientific Peroxidase Suppressor                  | Fisher Scientific       | Cat# PI35000                     |
| Gibco TrypLE Express Enzyme (1X), no phenol red          | Fisher Scientific       | Cat# 12-604-013                  |
| Noble agar, molecular biology and tissue culture grade   | Fisher Scientific       | Cat# 50-488-478                  |
| Taq DNA Polymerase with Standard Taq Buffer              | NEB                     | Cat# M0273                       |
| Gibco DMEM, powder, high glucose, pyruvate               | Fisher Scientific       | Cat# 12-800-017                  |
| Nitro blue Tetrazolium Chloride                          | ThermoFisher Scientific | Cat# N6495                       |

(Continued on next page)

**Continued**

| REAGENT or RESOURCE  | SOURCE  | IDENTIFIER  |
|--|---|---|
| <b>Critical commercial assays</b>  |   |   |
| RNeasy Micro Kit   | QIAGEN  | Cat# 74004  |
| 4D-Nucleofector Kit  | Lonza   | Cat# 1032   |
| DNeasy Blood & Tissue Kit  | QIAGEN  | Cat# 69504  |
| Cell Line Nucleofector Kit V   | Lonza   | Cat# VCA-1003   |
| Pierce BCA Protein Assay Kit   | ThermoFisher Scientific                                       | Cat# 23225  |
| MinElute PCR Purification Kit  | QIAGEN  | Cat# 28004  |
| RNAscope Multiplex Fluorescent Reagent Kit v2                                | Advanced Cell Diagnostics                                     | Cat# 323100   |
| ImmPRESS HRP Goat Anti-Rabbit IgG Polymer Detection Kit, Peroxidase          | Vector Laboratories   | Cat# MP-7451  |
| RNeasy Mini Kit  | QIAGEN  | Cat# 74104  |
| RNeasy Micro Plus Kit  | QIAGEN  | Cat# 74034  |
| RT <sup>2</sup> HT First Strand Kit  | QIAGEN  | Cat# 330411   |
| <b>Deposited data</b>  |   |   |
| Raw data and analysis  | This paper  | GEO: GSE206039  |
| Zebrafish reference genome build 11, GRCz11                                  | Genome Reference Consortium                                   | RefSeq: GCF_000002035.6   |
| Mouse reference genome build 38, GRCm38                                      | Genome Reference Consortium                                   | RefSeq: GCF_000001635.20  |
| Human reference genome build 38 patch 4, GRCh38p4                            | Genome Reference Consortium                                   | RefSeq: GCF_000001405.30  |
| RNA-seq data from human VGLL2-NCOA2 and CIC-DUX4 tumors                      | Watson et al., 2018 <sup>4</sup>                              | EGA: EGAS00001002189  |
| RNA-seq data from human mature skeletal muscle                               | Broad Institute   | GTE Analysis Release V8   |
| RNA-seq of mouse mature skeletal muscle                                      | Tanner et al., 2021 <sup>28</sup>                             | BioProject: PRJNA625451   |
| RNA-seq of mouse mature skeletal muscle                                      | Chakraborty et al., 2020 <sup>29</sup>                        | BioProject: PRJNA608179   |
| RNA-seq of mouse mature skeletal muscle                                      |   | BioProject: PRJNA819493   |
| RNA-seq of mouse mature skeletal muscle                                      | Mao et al., 2022 <sup>30</sup>                                | BioProject: PRJNA813153;<br>GEO: GSE197972  |
| RNA-seq data from KRAS driven rhabdomyosarcoma zebrafish tumors and controls | Ignatius et al., 2018 <sup>48</sup>                           | GEO: GSE109581  |
| RNA-seq data for adult sarcomas  | Cancer Genome Atlas Research, 2017 <sup>49</sup>              | <a href="https://portal.gdc.cancer.gov/projects">https://portal.gdc.cancer.gov/projects</a> |
| RNA-seq data from Ewing sarcoma tumors                                       | Crompton et al., 2014 <sup>50</sup>                           | dbGaP: phs000804.v1.p1  |
| RNA-seq data from osteosarcoma tumors  | TARGET Initiative   | dbGaP: phs000468  |
| RNA-seq data from clear cell sarcoma of the kidney                           | TARGET Initiative   | dbGaP: phs000466  |
| RNA-seq data from fusion-positive and fusion-negative rhabdomyosarcoma       | Chen et al., 2013 <sup>51</sup>                               | EGA: EGAD00001000878  |
| Zebrafish developmental RNA-seq data   | White et al., 2017 <sup>26</sup>                              | ENA: ERP014517  |
| <b>Experimental models: Cell lines</b>                                       |   |   |
| C2C12 mouse myoblasts  | ATCC  | Cat# CRL-1722   |
| C2C12-pcDNA3.1 empty   | This paper  | N/A   |
| C2C12-VGLL2NCOA2   | This paper  | N/A   |
| Arf6 KO C2C12  | This paper  | N/A   |
| Arf6 KO C2C12-pcDNA3.1 empty   | This paper  | N/A   |
| Arf6 KO C2C12-VGLL2NCOA2   | This paper  | N/A   |
| <b>Experimental models: Organisms/strains</b>                                |   |   |
| Zebrafish: AB  | ZIRC  | Cat# ZL1  |
| Zebrafish: WIK   | ZIRC  | Cat# ZL84   |
| Zebrafish: TL  | ZIRC  | Cat# ZL86   |
| Zebrafish: tp53 <sup>M214K</sup>   | Laboratory of Tom Look (Berghmans et al., 2005) <sup>52</sup> | ZIRC: ZL1057  |

(Continued on next page)



| <b>Continued</b>  |   |   |
|---|---|---|
| REAGENT or RESOURCE   | SOURCE  | IDENTIFIER  |
| Mouse: CB17/Icr-Prkdc <sup>scid</sup> /IcrIcoCrI                | Charles River   | Cat# 236  |
| Mouse: Crl:NU(Ico)-Foxn1 <sup>nu</sup>                          | Charles River   | Cat# 620  |
| <b>Oligonucleotides</b>   |   |   |
| Arf6 gRNA (mouse):<br>TCTTCGGGAACAAGGAAATG                      | Synthego  | N/A   |
| Mouse Negative Control Primer Set 2                             | Active Motif  | Cat# 71012  |
| RNAscope Probe-Dr-myog  | Advanced Cell Diagnostics   | Cat# 895021   |
| RNAscope Probe-Dr-desma-C1                                      | Advanced Cell Diagnostics   | Cat# 1006941-C1   |
| RNAscope Probe-DR-myod1   | Advanced Cell Diagnostics   | Cat# 481231   |
| Primers for RT-PCR, cloning,<br>CRISPR/Cas9, ChIP-qPCR, qRT-PCR | See Table S5  | N/A   |
| <b>Recombinant DNA</b>  |   |   |
| pDestTol2pA2 destination vector                                 | Kwan et al., 2007 <sup>53</sup>                                       | N/A   |
| p3E_SV40 late polyA   | Kwan et al., 2007 <sup>53</sup>                                       | N/A   |
| p5E_beta actin  | Kwan et al., 2007 <sup>53</sup>                                       | N/A   |
| p5E_cmv   | Kwan et al., 2007 <sup>53</sup>                                       | N/A   |
| p5E_mcs   | Kwan et al., 2007 <sup>53</sup>                                       | N/A   |
| pENTR5'_ubi   | Laboratory of Leonard Zon<br>(Mosimann et al., 2011) <sup>54</sup>    | Addgene: 27320  |
| p5E_unc503  | Laboratory of Peter Currie<br>(Berger and Currie, 2013) <sup>55</sup> | Addgene: 64020  |
| pmE_beta globin splice acceptor                                 | Kawakami et al., 2004 <sup>56</sup>                                   | N/A   |
| pmE_GFP-viral2A   | Kendall et al., 2018 <sup>23</sup>                                    | N/A   |
| pCS2FA-transposase  | Laboratory of Koichi Kawakami<br>(Urasaki et al., 2006) <sup>25</sup> | N/A   |
| p3E_VGLL2NCOA2  | This paper  | N/A   |
| CMV-GFP2A-VGLL2NCOA2  | This paper  | N/A   |
| BetaActin-GFP2A-VGLL2NCOA2                                      | This paper  | N/A   |
| ubi-GFP2A-VGLL2NCOA2  | This paper  | N/A   |
| unc503-GFP2A-VGLL2NCOA2   | This paper  | N/A   |
| MCS-beta-globin-SpliceAcceptor-<br>GFP2A-VGLL2NCOA2             | This paper  | N/A   |
| Invitrogen pcDNA3.1(+) Mammalian<br>Expression Vector           | Fisher Scientific   | Cat# V79020   |
| pcDNA3.1(+)-VGLL2NCOA2  | This paper  | N/A   |
| <b>Software and algorithms</b>                                  |   |   |
| Code utilized in data analysis                                  | This paper  | <a href="https://github.com/MVesuviusC/2022_VGLL2_NCOA2_paper">https://github.com/MVesuviusC/2022_VGLL2_NCOA2_paper</a>                       |
| Benchling   | N/A   | <a href="https://www.benchling.com/">https://www.benchling.com/</a>   |
| ICE Analysis  | Synthego  | <a href="https://ice.synthego.com/#/">https://ice.synthego.com/#/</a>   |
| Trim Galore   | Babraham Institute  | <a href="https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/">https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/</a> |
| Bowtie 2 v2.3.4.3   | Langmead and Salzberg, 2012 <sup>57</sup>                             | <a href="https://bowtie-bio.sourceforge.net/bowtie2/index.shtml">https://bowtie-bio.sourceforge.net/bowtie2/index.shtml</a>                   |
| STAR v2.7.2b  | Dobin et al., 2013 <sup>58</sup>                                      | <a href="https://github.com/alexdobin/STAR/releases">https://github.com/alexdobin/STAR/releases</a>   |
| SAMtools v1.9   | Li et al., 2009 <sup>59</sup>   | <a href="https://github.com/samtools/">https://github.com/samtools/</a>   |
| Python  | Python  | <a href="https://www.python.org/downloads/">https://www.python.org/downloads/</a>   |
| HTSeq   | Anders et al., 2015 <sup>60</sup>                                     | <a href="https://pypi.org/project/HTSeq/">https://pypi.org/project/HTSeq/</a>   |

(Continued on next page)

**Continued**

| REAGENT or RESOURCE       | SOURCE   | IDENTIFIER  |
|---------------------------|--|---|
| R                         | The R Foundation   | <a href="https://www.r-project.org/">https://www.r-project.org/</a>   |
| Bioconductor              | Gentleman et al., 2004 <sup>61</sup>   | <a href="https://www.bioconductor.org/install/">https://www.bioconductor.org/install/</a>   |
| edgeR                     | McCarthy et al., 2012 <sup>62</sup> ;<br>Robinson et al., 2010 <sup>63</sup> | <a href="http://bioconductor.org/packages/release/bioc/html/edgeR.html">http://bioconductor.org/packages/release/bioc/html/edgeR.html</a>                                 |
| AGDEX                     | Pounds et al., 2011 <sup>27</sup>  | <a href="https://www.stjude.org/research/departments/biostatistics/software/agdex.html">https://www.stjude.org/research/departments/biostatistics/software/agdex.html</a> |
| Kallisto 0.46.1           | Bray et al., 2016 <sup>64</sup>  | <a href="http://pachterlab.github.io/kallisto/download">http://pachterlab.github.io/kallisto/download</a>   |
| Biomart                   | Ensembl  | <a href="https://www.ensembl.org/biomart/martview">https://www.ensembl.org/biomart/martview</a>   |
| ComBat                    | Zhang et al., 2020 <sup>65</sup>   | <a href="https://www.bioconductor.org/packages/release/bioc/html/sva.html">https://www.bioconductor.org/packages/release/bioc/html/sva.html</a>                           |
| DAVID                     | Huang da et al., 2009a,b <sup>66,67</sup>                                    | <a href="https://david.ncifcrf.gov/">https://david.ncifcrf.gov/</a>   |
| clusterProfiler R package | Wu et al., 2021 <sup>68</sup> ; Yu et al., 2012 <sup>69</sup>                | <a href="https://bioconductor.org/packages/release/bioc/html/clusterProfiler.html">https://bioconductor.org/packages/release/bioc/html/clusterProfiler.html</a>           |
| Prism 8.1.1               | GraphPad   | <a href="https://www.graphpad.com/">https://www.graphpad.com/</a>   |
| ImageJ                    | NIH  | <a href="https://imagej.nih.gov/ij/download.html">https://imagej.nih.gov/ij/download.html</a>   |

**RESOURCE AVAILABILITY**

**Lead contact**

Further information and request for resources and reagents should be directed to and will be fulfilled by the lead contact, Genevieve Kendall ([Genevieve.Kendall@NationwideChildrens.org](mailto:Genevieve.Kendall@NationwideChildrens.org)).

**Materials availability**

Requests for materials generated in this study should be directed to the **lead contact**, Genevieve Kendall ([Genevieve.Kendall@NationwideChildrens.org](mailto:Genevieve.Kendall@NationwideChildrens.org)), and are available with a completed Materials Transfer Agreement.

**Data and code availability**

- Zebrafish RNA-seq data have been deposited at GEO and are publicly available as of the date of publication. The accession number is listed in the **key resources table**. This paper also analyzes existing, publicly available data or data with access that is available upon request. Accession numbers for the datasets are listed in the **key resources table**. Original western blot images and microscopy data will be shared by the **lead contact** upon request.
- This paper does not report original code. The code used to analyze the data is available on GitHub ([https://github.com/MVesuviusC/2022\\_VGLL2\\_NCOA2\\_paper](https://github.com/MVesuviusC/2022_VGLL2_NCOA2_paper)).
- Any additional information required to reanalyze the data reported in this paper is available from the **lead contact** upon request.

**EXPERIMENTAL MODEL AND SUBJECT DETAILS**

**Zebrafish**

*Danio rerio* were housed in an AAALAC-accredited, USDA-registered, OLAW-assured Aquaneering facility in compliance with the Guide for the Care and Use of Laboratory Animals. Vertebrate animal work was overseen by the UT Southwestern Medical Center or the Abigail Wexner Research Institute at Nationwide Children's Hospital IACUC committee and Animal Resources Core. Zebrafish are free of *Pseudoloma neurophilia*, *Pleistophora hyphessobryconis*, *Pseudocapillaria tomentosa*, *Mycobacterium spp.*, *Edwardsiella ictalurid*, *Ichthyophthirius multifiliis*, *Flavobacterium columnare*, and zebrafish picornavirus (ZFPV1) as determined by a quarterly sentinel monitoring program. The fish were housed at a density of 5–12 fish per liter in mixed-sex groups in 0.8-L, 1.8-L, 2.8-L, or 6-L tanks on a recirculating system (Aquaneering, San Diego, CA) in 28°C water (conductivity, 510 to 600 µS; pH, 7.3 to 7.7; hardness, 80 ppm; alkalinity, 80 ppm; dissolved oxygen, greater than 6 mg/L; ammonia, 0 ppm; nitrate, 0 to 0.5 ppm; and nitrite, 0 ppm) in a

room with a 14:10-h light:dark cycle. System water was carbon-filtered municipal tap water, filtered through a 20- $\mu$ m pleated particulate filter, and exposed to 40W UV light. As juveniles (5–30 days) the fish were fed live rotifer reeds, and as adults (>30 days) fish were fed twice daily with a commercial pelleted diet. Both male and female zebrafish were utilized in single-cell injection experiments since zebrafish sex is not determined until 30–60 days of age in our facility. Wild-type lines used in this study were AB, WIK, TL and were obtained from the Zebrafish International Resource Center (ZIRC). AB/TL were bred in our facility by crossing AB and TL. The *p53* mutant line, *tp53*<sup>M214K</sup>, was a kind gift from Tom Look.<sup>52</sup>

### Mice

Animal care and use for this study were performed in accordance with the recommendations of the European Community (2010/63/UE) for the care and use of laboratory animals. Experimental procedures were specifically approved by the ethics committee of the Institut Curie CEEA-IC #118 (Authorization APAFIS#11206-2017090816044613-v2 given by National Authority) in compliance with international guidelines. Mouse strains used were SCID (Charles River Laboratories CB17/lcr-Prkdc<sup>scid</sup>/lcrIcoCrI) or Swiss Nude (Charles River Laboratories CrI:NU(lco)-Foxn1<sup>nu</sup>) mice. All injected mice were female and, except for one Nude mouse at 136 days of age, were 46 days old at the time of injection.

### Cells

C2C12 mouse myoblast cells were obtained from American Type Culture Collection (#CRL-1722) and were cultured in growth media consisting of 10% or 20% fetal bovine serum in DMEM (GE healthcare #SH30022.01 or Gibco #11995065). Cells were maintained in a humidified incubator at 37°C with 5% CO<sub>2</sub>. Cell identity was verified by STR profiling and was confirmed negative by qPCR for mycoplasma through Genetica (Lab Corp).

### Human sarcoma and skeletal muscle samples

Previously generated human sarcoma or mature skeletal muscle RNA-seq data was used in this paper. The accession numbers are provided in the key resources table and data are available upon request from the original depositor.

## METHOD DETAILS

### Plasmids and cloning

*VGLL2-NCOA2* coding sequence was cloned out of a patient tumor. In the fusion used to develop the zebrafish model, exons 1 and 2 of *VGLL2* is fused to exon 14 through 23 of *NCOA2*. Sanger sequencing revealed that serine at position 544 of the resulting fusion protein had the nucleotide sequence TCT, a silent mutation compared to the human reference sequence of TCC. The fusion was cloned into the Gateway expression system by adding 5' and-3' ATT sites (*attb2r/attb3*) using a high-fidelity polymerase. Purified PCR product was then cloned into a 3' entry clone as described in Kendall and Amatruda, 2016.<sup>70</sup> The Tol2 kit components: destination vector pDestTol2pA2, 3' SV40 late polyA signal construct, beta actin promoter, cmv promoter, and multiple cloning site were used to generate constructs for expression in zebrafish.<sup>53</sup> The ubi promoter was a kind gift from Len Zon (Addgene #27320),<sup>54</sup> and the unc503 promoter from Peter Currie (Addgene #27320).<sup>55</sup> Middle entry beta globin intron and splice acceptor was from Koichi Kawakami.<sup>56</sup> The GFP-viral2A sequence were a gift from Steven Leach<sup>71</sup> and were sub-cloned into a middle entry Gateway expression system.<sup>23</sup> Tol2 mRNA was synthesized *in vitro* from pCS2FA-transposase which is from Koichi Kawakami.<sup>25</sup> The CMV-GFP2A-pA construct was generated as described in Kendall et al., 2018.<sup>23</sup> The zebrafish expression constructs generated for this study include: CMV-GFP2A-VGLL2NCOA2, BetaActin-GFP2A-VGLL2NCOA2, ubi-GFP2A-VGLL2NCOA2, unc503-GFP2A-VGLL2NCOA2, MCS-beta-globin-SpliceAcceptor-GFP2A-VGLL2NCOA2. For expression in C2C12 cells, the *VGLL2-NCOA2* fusion was sub-cloned into pcDNA3.1 using primers that added BamH1 and Xho1 digest sites to the 5' and-3' ends of the transcript, respectively (Table S5).

### Zebrafish embryo injections

Zebrafish embryos were injected at the single-cell stage with an injection mix containing 50 ng/ $\mu$ L of Tol2 transposase mRNA, 50 ng/ $\mu$ L of the *VGLL2-NCOA2* DNA construct and equimolar amounts of control constructs, 0.1% phenol red and 3x Danieau's buffer.

### Zebrafish tumor collection and processing

Zebrafish with tumors were euthanized in 2 mg/mL Tricaine-S solution and screened using the Nikon SMZ25 fluorescent stereoscope to detect GFP expression. Tumors were resected and flash frozen in liquid nitrogen. Total RNA isolation was performed on frozen tissue using the RNeasy Micro Kit (Qiagen #74004). The remaining zebrafish was fixed in 4% paraformaldehyde in PBS for 48 h shaking at 4°C, subsequently decalcified in 0.5M EDTA for 5 days at room temperature and mounted in paraffin blocks for microtome sectioning. Sections were taken at 5–10 micron intervals. De-paraffinized slides were stained with hematoxylin and eosin as described in Kendall and Amatruda, 2016.<sup>70</sup>



### Zebrafish tumor incidence

All zebrafish that survived past thirty days were counted for tumor incidence curves. Zebrafish with no GFP fluorescence were counted as negative for transgene-dependent tumor formation. Zebrafish with GFP fluorescence were processed as described earlier and tumor formation was confirmed by visual review by a pathologist of hematoxylin and eosin stained slides. Fish tumors were classified by location (Figure 1C): tumors anterior to the gill were considered head tumors, and tumors posterior to the largest part of the ventral fin were considered tail tumors. Tumors between these two boundaries were divided into back tumors and ventral tumors at the midcoronal plane. Tumors spanning more than one area were classified by the area in which the tumor predominately presented.

### Generation of genetically modified C2C12 cell lines

Knockout of Arf6 in the C2C12 was performed as follows: guides were designed targeting Arf6 in Benchling and the most efficient predicted gRNA was utilized with the sequence TCTTCGGGAACAAGGAAATG (Synthego). The 4D-Nucleofector Kit (Lonza #1032) was used to electroporate HiFi Cas9 nuclease (IDT #1081061), Arf6 gRNA, and the Electroporation Enhancer (IDT #1075916) into 200,000 C2C12 cells using the Lonza 4D-Nucleofector system. Control wild-type cells were electroporated without the Cas9/RNP complex. To confirm the gene editing efficiency, PCR was performed around the target sequence, Sanger sequenced, and Inference of CRISPR Edits (ICE) analysis (Synthego) suggested multiple knockout alleles. These populations (both control and Arf6 knockout cells) were utilized for generating monoclonal cell populations using cloning by limiting dilution. From monoclonal populations, DNA was isolated using the DNeasy Blood and Tissue Kit (QIAGEN #69504), PCR and Sanger sequencing performed to identify a one base pair A insertion at the 40<sup>th</sup> nucleotide relative to the start codon, resulting in premature stop and a 109 amino acid Arf6 protein as compared to the full-length 176 amino acid protein. Arf6 protein knockout was confirmed by western blot. In Figure 6, wild-type C2C12 cells were transfected with pcDNA3.1 empty vector or pcDNA3.1 containing the human coding sequence of the VGLL2-NCOA2 fusion using the AMAXA cell line Nucleofection kit V (Lonza #VCA-1003) and were selected in growth media containing 1 mg/mL concentration of G418 (ThermoFisher #10131035). Cells expressed the VGLL2-NCOA2 fusion at 24 h post transfection and stably after passage in culture under G418 selection. In Figure 7, wild-type and Arf6 knockout cells were transfected using the GenJet In Vitro DNA Transfection Reagent for C2C12 Cells (SigmaGen Laboratories # SL100489-C2C12) with either the pcDNA3.1 empty plasmid or the VGLL2-NCOA2 expressing pcDNA3.1 plasmid. Cells were selected for over two weeks in growth media (DMEM + 10% FBS) with 1 mg/mL Geneticin/G418 (Gibco #10131027).

### Western blot

In Figure 6, C2C12 cell lysate was generated using 5 million cells in RIPA lysis buffer with protease/phosphatase inhibitors (Roche #11836145001 and #04906837001), and 20 $\mu$ g of protein was loaded on a denaturing SDS page gel for detection of the VGLL2-NCOA2 fusion. Western blot was performed using primary antibodies against human NCOA2 at 1:5000 dilution (Abcam #ab10508) and anti Beta Actin at 1:10000 dilution (Sigma #A5316), and were visualized using monoclonal anti-Rabbit (1:3000) secondary, and chemiluminescence on film. In Figure 7, C2C12 cells were lysed in RIPA buffer and 1X protease/phosphatase inhibitors with brief use of a pestle (Sigma #R0278 and Thermo Scientific #78446), rocked at 4°C for 20 min, and centrifuged at 15000 g at 4°C for 15 min. Protein concentration was determined by Pierce BCA Protein Assay Kit (ThermoFisher Scientific, #23225). A pre-cast 4–15% gradient gel (Bio-Rad #4561084) was loaded with 10 $\mu$ L of Precision Plus Protein Dual Color Standard (Bio-Rad #1610374), 18 $\mu$ g of protein lysate, and ran in 1X Tris/Glycine/SDS buffer (Bio-Rad #1610772). The gel was transferred to an Immun-Blot PVDF membrane (Bio-Rad #1620177), blocked with 5% milk + 0.1% Tween in 1X Tris-Buffered Saline (TBS), and incubated with 1:1000 primary rabbit polyclonal anti-KAT13C/NCOA2 antibody (Abcam #ab10508) in Casein + 0.05% Tween overnight at 4°C (ThermoScientific #37528). Membranes were then washed and incubated with 1:10000 goat anti-rabbit IgG (Bio-Rad #1721019) secondary antibody in Casein + 0.05% Tween for 1 h at room temperature. For chemiluminescence visualization we used SuperSignal<sup>TM</sup> West Atto Ultimate Sensitivity Substrate (ThermoScientific # PI34577) and imaged on the LI-COR C-DiGit Blot Scanner. After imaging, the membrane was stripped for 15 min with the Thermo Scientific<sup>TM</sup> Restore<sup>TM</sup> Western Blot Stripping Buffer (ThermoScientific #PI21059), washed, and incubated with either 1:1000 alpha-Tubulin (DM1A) Mouse mAb (Cell Signaling #3873S) or 1:1000 Anti-ARF6 antibody (Abcam #ab226389) in Casein + 0.05% Tween at 4°C overnight. For Tubulin, a dilution of 1:10000 goat anti-mouse IgG secondary antibody was used (Bio-Rad #1706516) and for ARF6, a dilution of 1:10000 goat anti-rabbit IgG secondary antibody (Bio-Rad #1721019). Secondary antibodies were diluted in Casein + 0.05% Tween and the membrane was incubated for 1 h at room temperature. Imaging was performed as above. In Figure 5, adult zebrafish were euthanized, and skeletal muscle or tumors extracted and snap-frozen. To isolate protein, skeletal muscle and tumors were homogenized in the T-PER<sup>TM</sup> Tissue Protein Extraction Reagent (ThermoFisher Scientific #78510) and rotated at 4°C for 2 h. Protein concentrations were obtained by Pierce<sup>TM</sup> BCA Protein Assay Kit (ThermoFisher Scientific #23225). Wild-type AB embryos at 24 h post fertilization were collected, dechorionated, deyolked with 55 mM NaCl, 1.8 mM KCl, 1.25 mM NaHCO<sub>3</sub>, washed with 0.5X Danieau's buffer (29 mM NaCl, 0.35 mM KCl, 0.2 mM MgSO<sub>4</sub>·4H<sub>2</sub>O, 0.3 mM Ca(NO<sub>3</sub>)<sub>2</sub>·4H<sub>2</sub>O, 2.5 mM HEPES), and snap-frozen.<sup>72</sup> Western blot was performed with 25 $\mu$ g of skeletal muscle protein, 25 $\mu$ g of tumor protein, and 12, 24 h post fertilization embryos. Samples were run in duplicate to quantify loading with QC Colloidal Coomassie (Bio-Rad cat#1610803) overnight. Membrane was incubated with 1:1000 anti-ARF6 (Abcam #ab226389) and visualized with 1:10000 anti-rabbit (Bio-Rad #1721019) on LI-COR C-DiGit Blot Scanner. Western blots were quantified by densitometry analysis in ImageJ.

### ChIP-qPCR

ChIP-qPCR protocol is adapted from Sunkel et al., 2021.<sup>73</sup> Transfected C2C12 cells were cultured in T175 flasks, detached with TrypLE Express, and washed with dPBS. Cells were re-suspended in dPBS and fixed in 1% formaldehyde solution for 10 min at room temperature. Fixation was quenched by adding glycine to a final concentration of 125mM and incubating on ice for 5 min. Cells were aliquoted, snap-frozen with dry ice, and stored at  $-80^{\circ}\text{C}$  until sonication. Six million cells per sample were thawed and suspended in 800 $\mu\text{L}$  of TE buffer, pH 8.0 with protease inhibitors. Cells were placed into a cooling block in a polystyrene micro centrifuge tube and sonicated with an Active Motif EpiShear probe sonicator at 30% amplitude with a 30 s on/off cycle for 25 min. 5  $\mu\text{L}$  of sonicated DNA was taken from each sample as an input. Crosslinks were reversed by adding 20  $\mu\text{L}$  TE, 1  $\mu\text{L}$  10% SDS, and 1  $\mu\text{L}$  18.5 mg/mL Proteinase K and incubating overnight at  $65^{\circ}\text{C}$ . Sonication and DNA fragmentation were evaluated using E-Gel 2% EX agarose gel system after purification with a Qiagen MinElute PCR Purification kit. Following fragmentation, 300 $\mu\text{L}$  of chromatin in TE buffer was taken and modified into a ChIP buffer with a final concentration of 1% Triton X-100, 0.1% SDS, 0.1% sodium deoxycholate, and 200mM NaCl. Chromatin was incubated on ice for 5 min and centrifuged at 13,000 rpm at  $4^{\circ}\text{C}$  for 10 min. Supernatant was moved to a new micro centrifuge tube and incubated with 2  $\mu\text{g}$  of H3K27Ac antibody (Active Motif # 39133) for 2 h with overhead rotation at  $4^{\circ}\text{C}$ . 40 $\mu\text{L}$  of Protein G Dynabeads, suspended in the previous mentioned ChIP buffer, were added to each sample and incubation continued overnight. Samples were wash twice in TE with 0.1% SDS, 0.1% sodium deoxycholate, and 1% Triton X-100, twice in TE with 1% Triton X-100, 0.1% SDS, 0.1% sodium deoxycholate, and 200mM NaCl, and twice in TE with 250mM LiCl, 0.5% NP-40, 0.5% sodium deoxycholate. Samples were suspended in 100  $\mu\text{L}$  TE buffer and reverse cross-linked overnight at  $65^{\circ}\text{C}$  with the addition of 2.5  $\mu\text{L}$  10% SDS and 5  $\mu\text{L}$  18.5 mg/mL Proteinase K. DNA was purified with a Qiagen MinElute PCR Purification kit. ChIP was analyzed by qPCR using iTaq Universal SYBR Green Supermix on a BioRad CFX384<sup>TM</sup> Real-Time Thermal Cycler. Equal volumes of ChIP and input DNA were diluted and run in triplicate using the primers in Table S5. Fold enrichment was calculated compared to a negative locus control (Active Motif #71012).

### Mouse allograft experiments and tumor processing

C2C12-pcDNA3.1 control and C2C12-pcDNA3.1-VGLL2NCOA2 cell lines were utilized in allograft experiments. Two million cells were resuspended in 50 $\mu\text{L}$  of sterile 1X PBS and injected intramuscularly into the leg of SCID (Charles River Laboratories CB17/Icr-Prkdc<sup>scid</sup>/IcrIcoCrI) or Swiss Nude (Charles River Laboratories CrI:NU(Ico)-Foxn1<sup>nu</sup>) mice under anesthesia. All injected mice were female and, except for one Nude mouse at 136 days of age, were 46 days old at the time of injection. Tumors were detected eleven days after injection, after which the height and width of the injected leg were measured using calipers to calculate the volume until 60 days post injection for C2C12 controls, and until 26 or 28 days post injection for C2C12-VGLL2NCOA2 injected mice (initial leg volume was 50–100mm<sup>3</sup>). At these later timepoints mice were euthanized due to tumor burden (C2C12-VGLL2NCOA2) or due to the end of the experiment (C2C12-pcDNA3.1 control). Tumor or control tissue was snap frozen in liquid nitrogen, and RNA isolated with Trizol for RNA-seq analysis. For immunohistochemistry, tumors were fixed in AFA (70% pure ethanol, 20% 4% formaldehyde solution, 10% glacial acetic acid) and mounted in paraffin blocks for microtome sectioning.

### In situ hybridization and immunofluorescence

Fluorescent *in situ* hybridization of *myog* (ACD Bio #895021), *desma* (ACD Bio #1006941-C1), and *myod1* (ACD Bio #481231) was performed using RNAscope Multiplex Fluorescent Reagent Kit v2. on 8  $\mu\text{m}$  transverse sections of VGLL2-NCOA2 tumor and wild-type zebrafish (ACD Bio #323100). RNAscope hybridizations were done according to manufacturer's instructions for formalin-fixed paraffin-embedded tissue with the following changes. Protease Plus was applied for 20 min instead of 30 min and Opal 520 (Fisher #NC1601877) was used with TSA dilution solution. After applying HRP blocker, immunofluorescence was performed. Slides were blocked at room temperature for 1 h in block solution (3% donkey serum, 0.1% Triton X-100, in 1X PBS). Slides were then incubated overnight at  $4^{\circ}\text{C}$  in antibody solution (1% donkey serum, 0.05% Tween 20, in 1XPBS) with anti-PCNA antibody at 1:500 dilution (Sigma Aldrich #MABE288). Slides were washed 3x for 10 min each in 1XPBS, then incubated for 2 h at room temperature in antibody solution with Cy3-conjugated donkey anti-mouse antibody at 1:100 (Jackson ImmunoResearch #715165150). Slides were washed 3x for 10 min each, then mounted with Invitrogen Prolong Gold Antifade with DAPI (Fisher #P36935). RNAscope and immunofluorescence samples were imaged using a Nikon Eclipse Ti2-E inverted microscope. Higher magnification images were taken using a 40X Plan Apo  $\lambda$  objective. 16-bit mode was used for DAPI, GFP, and Cy-3 channels. Images were processed with the following settings using Nikon GA3 analysis: Detect Peaks with count 10 was used for DAPI, and Rolling Ball with 10 $\mu\text{m}$  radius was used for GFP and Cy3.

### Immunohistochemistry

For zebrafish sections, slides were baked in a  $60^{\circ}\text{C}$  oven for 1 h, deparaffinized with xylene/Histo-Clear for two incubations of 10 min, rehydrated in two 3 min washes in 100% Ethanol, 95% Ethanol and then diH<sub>2</sub>O. Antigen retrieval was performed in Trilogy reagent for 15 min in a pressure cooker. The slides were incubated with 3% peroxidase H<sub>2</sub>O<sub>2</sub> for 30 min, washed with water for 1 min, blocked with 1% BSA/1x PBST for 1 h. Primary antibody incubation was done at 1:100 dilution at  $4^{\circ}\text{C}$  overnight. Primary antibodies used were anti-NCOA2 (Novus BIO #NB100-1756) and anti-ARF6 (Abcam #ab77581). Slides were washed with PBST 4 times for 5 min each, and HRP secondary conjugate (BioRad #1721019) was applied at 1:300 dilution for 1 h at room temperature. Washes were performed as above, and DAB solution (Sigma #D5905) with 0.03% H<sub>2</sub>O<sub>2</sub> applied for 5 min. Slides were counterstained with hematoxylin for

5 min and dehydrated in 95% Ethanol, 100% Ethanol, and Xylene/Histo-Clear each for two incubations of 1 min each. Slides were imaged on a Keyence BZ-X710 microscope or a Leica Aperio GT 450. For mouse allograft Desmin, Myogenin, and Ki67 stains, immunohistochemistry was performed using the DAKO Autostainer Link 48 (Agilent Technologies) with the following antibody conditions for each protein target: Desmin, D33 clone (Dako #M0760), pH6 retrieval, 1:200 primary dilution and 30 min incubation; Myogenin, F5D clone (Dako #GA067), pH9 retrieval, 1:100 primary antibody dilution and 60 min incubation. The Ki67 stain was performed using the Bond RX immunostainer and Bond Polymer Refine Detection Kit (Leica Microsystems). The antibody used for Ki67 was SP6 clone (Abcam #16667) with pH9 retrieval, 1:1000 primary antibody dilution and 30 min incubation. Slides were digitized using the Ultra Fast 1.6 RA scanner (Philips, Best, Netherlands). For the mouse allograft Arf6 stain, slides were baked in a 60°C oven for 1 h, deparaffinized with xylene/Histo-Clear for two incubations of 10 min, rehydrated in two 3 min washes in 100% Ethanol, 95% Ethanol and then diH<sub>2</sub>O. Antigen retrieval was performed in 10 mM sodium citrate buffer pH 6.0 for 15 min in a pressure cooker. The slides were washed twice with PBS for 3 min then blocked with 3% BSA/1X PBST with 10% goat serum for 1 h. Primary antibody incubation was done at 1:100 dilution at 4°C overnight. The primary antibody used was anti-ARF6 (Novus BIO #NBP3-15391). Slides were washed with PBST 4 times for 5 min each and incubated with Thermo Scientific Peroxidase Suppressor (Fisher #PI35000) for 30 min and rinsed twice with water for 3 min. ImmPRESS HRP (Vector Labs #MP-7451) was then applied for 30 min at room temperature. PBST washes were performed as above, and DAB solution (Sigma #D5905) with 0.03% H<sub>2</sub>O<sub>2</sub> was applied for 3 min. Slides were counterstained with hematoxylin for 5 min and dehydrated in 95% Ethanol, 100% Ethanol, and Xylene/Histo-Clear each for two incubations of 1 min each and were scanned using an Aperio GT 450 (Leica).

### Cellular proliferation of C2C12 *in vitro*

Arf6 KO C2C12 cells and WT C2C12 cells, either with or without expression of the VGLL2-NCOA2 fusion, were seeded at a density of 500,000 or 200,000 cells in T175 flasks. Cells were maintained in growth media, supplemented with 1 mg/mL G418 (Fisher). After 2 or 3 days, respectively, cells were incubated with TrypLE Express Enzyme (Fisher #12604013) and then live cells were counted on a Countess Automated Cell Counter (ThermoFisher) with a trypan blue stain.

### Myogenic differentiation of C2C12 *in vitro*

C2C12 cells were differentiated by plating 150,000 cells per well in growth media + G418 on 6-well plates coated with 0.1% porcine gelatin/1X PBS. After 48 h, cells were washed in 1X PBS, and differentiation media + G418 was added. Cells were then fused for 6 days in differentiation media (1X DMEM + 10% horse serum + 10 μg/mL insulin + 1 mg/mL G418), with fresh media being added every other day. For fusion timepoints, cells were collected and pelleted after incubation in TrypLE Express Enzyme (Fisher #12604013), and then were snap frozen for total RNA isolation.

### Soft agar colony formation

Colony formation protocol was adapted from Borowicz et al., 2014.<sup>74</sup> Briefly, in a 6-well plate a bottom layer of 1% noble agar in growth media + 1 mg/mL G418 was plated and allowed to solidify. This was followed by a top layer of 0.6% noble agar + growth media (DMEM + 10% FBS + 1 mg/mL Geneticin/G418) containing either 5000 or 10000 cells per well. The top layer was allowed to solidify, and 100 μL of growth media + G418 was added to the top of each well. To prevent drying out, 100 μL of growth media + G418 was added every 2–3 days. Colonies were counted manually using a Leica DMIL LED inverted microscope two weeks after plating.

### RNA isolation, RT-PCR and qRT-PCR

RNA was isolated from zebrafish tumors, normal tissue, or embryos using the QIAGEN RNeasy micro or mini-kit depending on the tumor size. For skeletal muscle, an additional proteinase K digestion step was included. 500 ng of RNA isolated from zebrafish tumors, normal tissue or  $n = 30$  embryos at 20 h post fertilization was used as input to the RT<sup>2</sup> HT First Strand Kit (Qiagen #330411) to reverse transcribe cDNA. For C2C12 cells, total RNA was isolated from using the RNeasy Mini or Micro Plus Kit (QIAGEN #74104 or #74034). cDNA was reverse transcribed from 1 μg of total RNA with the RT<sup>2</sup> HT First Strand Kit (QIAGEN #330411). Standard PCRs were run using Taq Polymerase (NEB #M0273). qRT-PCR was performed on the BioRad CFX384 using standard cycling conditions and the 2X BioRad Master Mix. Primer sequences are provided in Table S5. Data was analyzed in CFX Maestro Software and are plotted as the values relative to zero as normalized to two input controls, *rplp13a* and *gapdh* for zebrafish samples, or *Rpl27* and *Gapdh* for mouse samples.

### RNA sequencing and analysis

Approximately 2 μg of RNA was used for library preparation of each zebrafish sample. RNA-seq for D738, D739, D742, D777, D799, D800, D801, D807, D808, D813, Muscle 2 and Muscle 3 was done at the Institut Curie. Total RNA was isolated from Nude C2C12-pcDNA3.1 control or C2C12-VGLL2NCOA2 allografts using Trizol, and approximately 1 μg was used for RNA-seq at the Institut Curie. D809, D811, D812, D814, D815, D874, and additional five mature skeletal muscle samples (D948, D949, D950, D951, D952) were sent to DNALinks for mRNA sequencing with poly-A RNA enrichment (2x75bp run, 70M reads of data generation). All tumors were generated in an AB/TL wild-type background, except for D738 and D742 which are in the *tp53*<sup>M214K</sup> homozygous mutant background.<sup>52</sup> Additional sample details are in Table S6. Trim Galore ([https://www.bioinformatics.babraham.ac.uk/projects/trim\\_galore/](https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/))



was used for quality and adapter trimming. The qualities of RNA-sequencing libraries were estimated by mapping the reads onto zebrafish reference dataset (Genome Reference Consortium Zebrafish Build 11, GRCz11) using Bowtie (v2.3.4.3)<sup>58</sup>. STAR (v2.7.2b)<sup>58</sup> was employed to align the reads onto the zebrafish genome GRCz11, mouse samples to *Mus musculus* GRCm38 genome, or human samples to the *Homo sapiens* GRCh38p4 genome. SAMtools (v1.9)<sup>60</sup> was employed to sort the alignments and HTSeq Python package<sup>60</sup> was employed to count reads per gene. edgeR R Bioconductor package<sup>61–63</sup> was used to normalize read counts and identify differentially expressed (DE) genes. The enrichment of DE genes to pathways and GOs were calculated by Fisher's exact test in R statistical package.<sup>75</sup> Differentially expressed genes were determined using cut-offs of fold changes >1.5 and an FDR of <0.05.

### Comparative oncology RNA-seq analysis

Agreement of Differential Expression (AGDEX)<sup>27</sup> analysis was performed using RNA-seq data generated in this study and from previously published sources. The following AGDEX comparisons were made: zebrafish VGLL2-NCOA2 tumors vs mature skeletal muscle and human VGLL2-NCOA2 tumors vs mature skeletal muscle; zebrafish VGLL2-NCOA2 vs CIC-DUX4 tumors and human VGLL2-NCOA2 vs CIC-DUX4 tumors; zebrafish KRAS tumors vs controls and zebrafish VGLL2-NCOA2 tumors vs mature skeletal muscle; zebrafish KRAS tumors vs controls and human VGLL2-NCOA2 tumors vs mature skeletal muscle; mouse allograft VGLL2-NCOA2 tumors vs mature skeletal muscle and human VGLL2-NCOA2 tumors vs mature skeletal muscle. RNA-seq data from human VGLL2-NCOA2 and CIC-DUX4 tumors is previously published in Watson et al., 2018.<sup>4</sup> RNA-seq data from human mature skeletal muscle is from GTEx version 8. RNA-seq data from mouse mature skeletal muscle is previously published and can be accessed through NCBI BioProjects PRJNA625451,<sup>28</sup> PRJNA608179,<sup>29</sup> PRJNA819493, PRJNA813153.<sup>30</sup> RNA-seq data from KRAS driven rhabdomyosarcoma zebrafish tumors and controls is previously published in Ignatius et al., 2018.<sup>48</sup> All other data was generated through this study and can be accessed on GEO under the accession number GSE206039. Gene expression values for both RNA-seq series were assessed using Kallisto 0.46.1<sup>67</sup> using indexes of the *Homo sapiens* GRCh38p4 genome, *Mus musculus* GRCm38 genome, or *Danio rerio* GRCz11 genome. Mapping of the genes between the species was done using BioMart tool from the Ensembl website (<https://www.ensembl.org/biomart/martview>). AGDEX<sup>27</sup> analysis was performed with a minimum number of permutations set to 5000. To further assess the statistical significance between species' correlation of the differential expression results, we performed a permutation analysis. For each comparison, we counted the number of genes that changed in the same direction in both datasets (logFC>0 in both or logFC<0 in both). We then used kernel density functions to generate randomized data matching the distribution of the original data and counted how many genes changed in the same direction between the two simulated datasets. This was repeated 100,000 times and we counted the number of iterations where an equal or greater number of genes changed in the same direction. This number was divided by the number of iterations to calculate a p value for each comparison. Where no iteration had as many correlated genes as the real data, the p value was noted as  $p < 1 \times 10^{-5}$ . UMAP projections of RNA-seq data were generated in R using normalized RNA-seq read counts.

### Human sarcoma and skeletal muscle RNA-seq analysis

RNA-seq data from VGLL2-NCOA2 tumors is from Watson et al., 2018.<sup>4</sup> RNA-seq data for  $n = 264$  adult sarcomas is from TCGA and represents dedifferentiated liposarcoma, leiomyosarcoma, undifferentiated pleomorphic sarcoma, myxofibrosarcoma, malignant peripheral nerve sheath tumor, and synovial sarcoma.<sup>49</sup> RNA-seq data from  $n = 96$  Ewing sarcoma tumors is from Crompton et al., 2014,<sup>50</sup> RNA-seq data from  $n = 87$  Osteosarcoma (phs000468) and  $n = 13$  Clear Cell Sarcoma of the Kidney (phs000466) are based upon data generated by the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) (<https://ocg.cancer.gov/programs/target>) initiative, phs000468 and phs000466. The data used for this analysis are available at <https://portal.gdc.cancer.gov/projects>. RNA-seq data from  $n = 42$  fusion-positive and fusion-negative rhabdomyosarcoma is from Chen et al., 2013.<sup>51</sup> RNA-seq data from  $n = 396$  adult skeletal muscle samples are from the Genotype-Tissue Expression Project (GTEx). The GTEx Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. The data used for the analyses described in this manuscript in Figure 7 were obtained from the GTEx Portal in March 2018, and in Figures 2, 4, S3 and S6 were obtained from the GTEx portal in April 2022. The same computational analysis steps based on hg19 human reference genome data, as detailed in the RNA-seq and analysis section, were applied to process these tumor and muscle datasets side by side to minimize computational batch effects. In addition, we also applied ComBat<sup>65</sup> to remove batch effects. HTSeq Python package<sup>60</sup> was employed to count reads per gene. edgeR R Bioconductor package<sup>61–63</sup> was used to normalize read counts and calculate FPKM values.

### PCA of zebrafish tumors and developmental stages

Zebrafish developmental RNA-seq data were from White et al., 2017.<sup>26</sup> Zebrafish tumor and skeletal muscle sample RNA-seq data were generated from this study. To minimize the computational batch effect, FASTQ files from White et al., 2017<sup>26</sup> and this study were processed side by side with the same pipeline, as detailed in the RNA sequencing and analysis section. We then performed the Principal Component Analysis based on princomp package in R.

### Gene ontology analysis

In [Figure S4](#), genes with statistically significant expression changes were analyzed using DAVID (<https://david.ncifcrf.gov/>)<sup>66,67</sup> to identify enriched Gene Ontology (GO) terms (<http://www.geneontology.org/>). The direct biological process (top) and molecular function (bottom) ontology terms are listed for genes differentially regulated in zebrafish VGLL2-NCOA2 tumors versus skeletal muscle (FDR<0.1). In [Figures 2](#), [S3](#) and [S6](#), Gene Set Enrichment Analysis was performed using co-differentially expressed genes in zebrafish and human VGLL2-NCOA2 tumors or mouse and human VGLL2-NCOA2 tumors as compared to mature skeletal muscle<sup>76,77</sup> using the clusterProfiler R package.<sup>68,69</sup> We searched the Biological Processes (BP), Molecular Functions (MF) and Cellular Component (CC) subontologies.

### QUANTIFICATION AND STATISTICAL ANALYSIS

Analysis of survival curves, tumor incidence and onset curves, Fisher's exact test, and all experimental statistical tests was performed in Prism 8.1.1 (LaJolla, CA). Image analysis was performed in ImageJ. All other calculations were performed in R. Sample sizes and the statistical tests performed are provided in figures or figure legends.